US4816567A
(en)
|
1983-04-08 |
1989-03-28 |
Genentech, Inc. |
Recombinant immunoglobin preparations
|
US5336603A
(en)
*
|
1987-10-02 |
1994-08-09 |
Genentech, Inc. |
CD4 adheson variants
|
US5750375A
(en)
*
|
1988-01-22 |
1998-05-12 |
Zymogenetics, Inc. |
Methods of producing secreted receptor analogs and biologically active dimerized polypeptide fusions
|
US5567584A
(en)
*
|
1988-01-22 |
1996-10-22 |
Zymogenetics, Inc. |
Methods of using biologically active dimerized polypeptide fusions to detect PDGF
|
US6018026A
(en)
|
1988-01-22 |
2000-01-25 |
Zymogenetics, Inc. |
Biologically active dimerized and multimerized polypeptide fusions
|
US6685941B1
(en)
|
1988-11-23 |
2004-02-03 |
The Regents Of The University Of Michigan |
Methods of treating autoimmune disease via CTLA-4Ig
|
US5225538A
(en)
*
|
1989-02-23 |
1993-07-06 |
Genentech, Inc. |
Lymphocyte homing receptor/immunoglobulin fusion proteins
|
US6406697B1
(en)
|
1989-02-23 |
2002-06-18 |
Genentech, Inc. |
Hybrid immunoglobulins
|
US5242687A
(en)
*
|
1989-03-15 |
1993-09-07 |
Tkb Associates Limited Partnership |
Method of reducing cellular immune response involving T-cells using CD8-bearing antigen presenting cells
|
US7264944B1
(en)
|
1989-04-21 |
2007-09-04 |
Amgen Inc. |
TNF receptors, TNF binding proteins and DNAs coding for them
|
ES2238070T3
(es)
|
1989-04-21 |
2005-08-16 |
Amgen Inc. |
Receptor del tnf, proteina ligante del tnf y adn codante para estos.
|
IL95031A
(en)
|
1989-07-18 |
2007-03-08 |
Amgen Inc |
A method of producing a recombinant human necrotic factor absorber
|
US6143866A
(en)
*
|
1989-07-18 |
2000-11-07 |
Amgen, Inc. |
Tumor necrosis factor (TNF) inhibitor and method for obtaining the same
|
US6267964B1
(en)
*
|
1989-08-01 |
2001-07-31 |
Affibody Technology Sweden Ab |
Stabilized protein or peptide conjugates able to bond albumin having extended biological half-lives
|
US6541610B1
(en)
*
|
1989-09-05 |
2003-04-01 |
Immunex Corporation |
Fusion proteins comprising tumor necrosis factor receptor
|
NZ235148A
(en)
*
|
1989-09-05 |
1991-12-23 |
Immunex Corp |
Tumour necrosis factor receptor protein and dna sequences
|
US5395760A
(en)
*
|
1989-09-05 |
1995-03-07 |
Immunex Corporation |
DNA encoding tumor necrosis factor-α and -β receptors
|
US5945397A
(en)
*
|
1989-09-05 |
1999-08-31 |
Immunex Corporation |
Purified p75 (type II) tumor necrosis factor receptor polypeptides
|
US5605690A
(en)
*
|
1989-09-05 |
1997-02-25 |
Immunex Corporation |
Methods of lowering active TNF-α levels in mammals using tumor necrosis factor receptor
|
DE59010933D1
(de)
|
1989-09-12 |
2003-05-08 |
Hoffmann La Roche |
TFN-bindende Proteine
|
US5216132A
(en)
*
|
1990-01-12 |
1993-06-01 |
Protein Design Labs, Inc. |
Soluble t-cell antigen receptor chimeric antigens
|
US6552170B1
(en)
*
|
1990-04-06 |
2003-04-22 |
Amgen Inc. |
PEGylation reagents and compounds formed therewith
|
GB9022543D0
(en)
*
|
1990-10-17 |
1990-11-28 |
Wellcome Found |
Antibody production
|
DE4037837A1
(de)
*
|
1990-11-28 |
1992-06-04 |
Behringwerke Ag |
Zellfreie rezeptorbindungsteste, ihre herstellung und verwendung
|
JP3670276B2
(ja)
|
1991-02-08 |
2005-07-13 |
プロゲニクス・ファーマスーティカルズ、インコーポレイテッド |
CD4― ガンマ・2キメラ及びCD4 ― IgG2・キメラ
|
US7070991B2
(en)
*
|
1991-02-08 |
2006-07-04 |
Progenics Pharmaceuticals, Inc. |
Cells expressing a CD4-IgG2 chimeric heterotetramer
|
MX9203138A
(es)
*
|
1991-03-12 |
1992-09-01 |
Biogen Inc |
Dominio de enlace cd2-de antigeno 3 (lfa-3) asociado con funcion linfositos.
|
DK0503648T3
(da)
*
|
1991-03-12 |
2000-10-30 |
Biogen Inc |
CD2-bindingsdomæne af lymfocytfunktion-associeret antigen 3
|
US20030206899A1
(en)
*
|
1991-03-29 |
2003-11-06 |
Genentech, Inc. |
Vascular endothelial cell growth factor antagonists
|
US6582959B2
(en)
*
|
1991-03-29 |
2003-06-24 |
Genentech, Inc. |
Antibodies to vascular endothelial cell growth factor
|
US5318890A
(en)
*
|
1991-05-06 |
1994-06-07 |
The Regents Of The University Of California |
Assays for inhibitors of leukocyte adhesion
|
US6797492B2
(en)
|
1991-05-17 |
2004-09-28 |
Merck & Co., Inc. |
Method for reducing the immunogenicity of antibody variable domains
|
US5844095A
(en)
*
|
1991-06-27 |
1998-12-01 |
Bristol-Myers Squibb Company |
CTLA4 Ig fusion proteins
|
US5851795A
(en)
*
|
1991-06-27 |
1998-12-22 |
Bristol-Myers Squibb Company |
Soluble CTLA4 molecules and uses thereof
|
EP0533006A1
(de)
*
|
1991-09-18 |
1993-03-24 |
F.Hoffmann-La Roche & Co. Aktiengesellschaft |
Chimäre Interleukin 5-Rezeptor/Immunoglobulin-Polypeptide
|
US6764681B2
(en)
*
|
1991-10-07 |
2004-07-20 |
Biogen, Inc. |
Method of prophylaxis or treatment of antigen presenting cell driven skin conditions using inhibitors of the CD2/LFA-3 interaction
|
US5871734A
(en)
*
|
1992-01-13 |
1999-02-16 |
Biogen, Inc. |
Treatment for asthma with VLA-4 blocking agents
|
US6399368B1
(en)
|
1992-01-17 |
2002-06-04 |
Board Of Regents, The University Of Texas System |
Secretion of T cell receptor fragments from recombinant Escherichia coli cells
|
FR2686899B1
(fr)
|
1992-01-31 |
1995-09-01 |
Rhone Poulenc Rorer Sa |
Nouveaux polypeptides biologiquement actifs, leur preparation et compositions pharmaceutiques les contenant.
|
US5932214A
(en)
*
|
1994-08-11 |
1999-08-03 |
Biogen, Inc. |
Treatment for inflammatory bowel disease with VLA-4 blockers
|
DE69333027T2
(de)
*
|
1992-03-30 |
2004-05-06 |
Immunex Corp., Seattle |
Fusionsprotein , das zwei rezeptoren des tumornekrose-faktors enthält
|
CA2118508A1
(en)
*
|
1992-04-24 |
1993-11-11 |
Elizabeth S. Ward |
Recombinant production of immunoglobulin-like domains in prokaryotic cells
|
US5540926A
(en)
*
|
1992-09-04 |
1996-07-30 |
Bristol-Myers Squibb Company |
Soluble and its use in B cell stimulation
|
WO1994005314A1
(en)
*
|
1992-09-08 |
1994-03-17 |
Centocor, Inc. |
Peptide inhibitors of leukocyte adhesion
|
CA2123593C
(en)
*
|
1992-09-15 |
2000-03-14 |
Craig A. Smith |
Method of treating tnf-dependent inflammation using tumor necrosis factor antagonists
|
DE69310525T2
(de)
*
|
1992-09-16 |
1997-10-02 |
Genentech Inc |
Schutz gegen leberschäden mit hgf
|
WO1994006469A1
(en)
*
|
1992-09-18 |
1994-03-31 |
La Jolla Institute For Allergy And Immunology |
Hiv fusion polypeptide
|
US6270766B1
(en)
|
1992-10-08 |
2001-08-07 |
The Kennedy Institute Of Rheumatology |
Anti-TNF antibodies and methotrexate in the treatment of arthritis and crohn's disease
|
US5474766A
(en)
*
|
1992-12-18 |
1995-12-12 |
Washington University |
Methods and compositions for inhibition of hepatic clearance of tissue-type plasminogen activator
|
WO1994014836A1
(en)
*
|
1992-12-18 |
1994-07-07 |
Centocor, Inc. |
Peptide inhibitors of selectin binding
|
CA2153802A1
(en)
*
|
1993-01-25 |
1994-08-04 |
Thomas F. Tedder |
Chimeric selectins as simultaneous blocking agents for component selectin function
|
US7534867B1
(en)
|
1993-05-19 |
2009-05-19 |
Schering Corporation |
Purified mammalian Flt3 ligands; agonists; antagonists
|
US6723705B1
(en)
|
1993-08-19 |
2004-04-20 |
Gentics Institute, Inc. |
Tumor cells modified to express B7-2 with increased immunogenicity and uses therefor
|
US5861310A
(en)
*
|
1993-11-03 |
1999-01-19 |
Dana-Farber Cancer Institute |
Tumor cells modified to express B7-2 with increased immunogenicity and uses therefor
|
US6130316A
(en)
*
|
1993-07-26 |
2000-10-10 |
Dana Farber Cancer Institute |
Fusion proteins of novel CTLA4/CD28 ligands and uses therefore
|
US6824779B1
(en)
|
1993-07-26 |
2004-11-30 |
Dana-Farber Cancer Institute, Inc. |
Methods for inhibiting the interaction of B7-2 with its natural ligand
|
US20050129670A1
(en)
*
|
1993-07-26 |
2005-06-16 |
Genetics Institute, Llc. |
Tumor cells modified to express B7-2 with increased immunogenicity and uses therefor
|
US6084067A
(en)
|
1993-07-26 |
2000-07-04 |
Dana-Farber Cancer Institute |
CTLA4/CD28 ligands and uses therefor
|
SE9302855D0
(sv)
*
|
1993-09-06 |
1993-09-06 |
Martin Lindberg |
Method and means for producing plasmaproteinase inhibitor binding proteins
|
WO1995014787A1
(en)
*
|
1993-11-22 |
1995-06-01 |
Centocor, Inc. |
Peptide inhibitors of selecting binding
|
DE69521789T2
(de)
*
|
1994-02-01 |
2002-04-25 |
Us Health |
Fusionierte proteine die antikörper-teile und nicht-antikörper-teile enthalten
|
US7294331B2
(en)
*
|
1994-03-07 |
2007-11-13 |
Immunex Corporation |
Methods of using flt3-ligand in hematopoietic cell transplantation
|
EP1025856A3
(de)
|
1994-03-08 |
2002-10-16 |
Dana-Farber Cancer Institute |
Verfahren zur Modulation von T-Zell Unempfänglichkeit
|
US5877016A
(en)
|
1994-03-18 |
1999-03-02 |
Genentech, Inc. |
Human trk receptors and neurotrophic factor inhibitors
|
IL113484A0
(en)
*
|
1994-04-28 |
1995-07-31 |
Immunex Corp |
Viral proteins pharmaceutical compositions containing them their preparation and use
|
USRE38313E1
(en)
|
1994-05-06 |
2003-11-11 |
Institut Gustave Roussy |
Soluble polypeptide fractions of the LAG-3 protein, production method, therapeutic composition, anti-idiotype antibodies
|
US6001968A
(en)
|
1994-08-17 |
1999-12-14 |
The Rockefeller University |
OB polypeptides, modified forms and compositions
|
US6309853B1
(en)
|
1994-08-17 |
2001-10-30 |
The Rockfeller University |
Modulators of body weight, corresponding nucleic acids and proteins, and diagnostic and therapeutic uses thereof
|
US6429290B1
(en)
|
1994-08-17 |
2002-08-06 |
The Rockefeller University |
OB polypeptides, modified forms and derivatives
|
US6471956B1
(en)
|
1994-08-17 |
2002-10-29 |
The Rockefeller University |
Ob polypeptides, modified forms and compositions thereto
|
US6124448A
(en)
*
|
1994-08-17 |
2000-09-26 |
The Rockfeller University |
Nucleic acid primers and probes for the mammalian OB gene
|
US6350730B1
(en)
|
1994-08-17 |
2002-02-26 |
The Rockefeller University |
OB polypeptides and modified forms as modulators of body weight
|
US6048837A
(en)
*
|
1994-08-17 |
2000-04-11 |
The Rockefeller University |
OB polypeptides as modulators of body weight
|
US5541087A
(en)
*
|
1994-09-14 |
1996-07-30 |
Fuji Immunopharmaceuticals Corporation |
Expression and export technology of proteins as immunofusins
|
US5814464A
(en)
*
|
1994-10-07 |
1998-09-29 |
Regeneron Pharma |
Nucleic acids encoding TIE-2 ligand-2
|
JPH11501506A
(ja)
*
|
1994-12-12 |
1999-02-09 |
ベス イスラエル デアコネス メディカル センター |
キメラ型サイトカインおよびその利用
|
US6410008B1
(en)
*
|
1994-12-12 |
2002-06-25 |
Beth Israel Hospital Association |
Chimeric IL-10 proteins and uses thereof
|
US6808709B1
(en)
*
|
1994-12-30 |
2004-10-26 |
The Regents Of The University Of California |
Immunoglobulins containing protection proteins and their use
|
US6030613A
(en)
*
|
1995-01-17 |
2000-02-29 |
The Brigham And Women's Hospital, Inc. |
Receptor specific transepithelial transport of therapeutics
|
US6086875A
(en)
*
|
1995-01-17 |
2000-07-11 |
The Brigham And Women's Hospital, Inc. |
Receptor specific transepithelial transport of immunogens
|
US6485726B1
(en)
*
|
1995-01-17 |
2002-11-26 |
The Brigham And Women's Hospital, Inc. |
Receptor specific transepithelial transport of therapeutics
|
US6455685B1
(en)
|
1995-03-03 |
2002-09-24 |
Millennium Pharmaceuticals, Inc. |
Compositions and methods for the treatment and diagnosis of immune disorders
|
US20030069196A1
(en)
*
|
1995-03-03 |
2003-04-10 |
Millennium Pharmaceuticals, Inc. |
Compositions and methods for the treatment and diagnosis of immune disorders
|
US6066322A
(en)
*
|
1995-03-03 |
2000-05-23 |
Millennium Pharmaceuticals, Inc. |
Methods for the treatment of immune disorders
|
US6211142B1
(en)
*
|
1995-03-10 |
2001-04-03 |
Genentech, Inc. |
Compositions comprising gas6 polypeptides and articles of manufacture comprising the same
|
US6680057B1
(en)
*
|
1995-03-23 |
2004-01-20 |
Immunex Corporation |
Methods of treating autoimmune disease by administering interleukin-17 receptor
|
DE69633617T3
(de)
*
|
1995-03-23 |
2010-05-20 |
Immunex Corp., Seattle |
Il-17 receptor
|
US20060193862A1
(en)
*
|
1995-03-30 |
2006-08-31 |
Genentech, Inc. |
Vascular endothelial cell growth factor antagonists
|
IL117645A
(en)
*
|
1995-03-30 |
2005-08-31 |
Genentech Inc |
Vascular endothelial cell growth factor antagonists for use as medicaments in the treatment of age-related macular degeneration
|
US7175847B1
(en)
*
|
1995-06-07 |
2007-02-13 |
Biogen Idec Inc. |
Treating intestinal inflammation with anti-CD80 antibodies that do not inhibit CD80 binding to CTLA-4
|
US7153508B2
(en)
*
|
1995-06-07 |
2006-12-26 |
Biogen Idec Inc. |
Treatment of B cell lymphoma using anti-CD80 antibodies that do not inhibit the binding of CD80 to CTLA-4
|
US6113898A
(en)
*
|
1995-06-07 |
2000-09-05 |
Idec Pharmaceuticals Corporation |
Human B7.1-specific primatized antibodies and transfectomas expressing said antibodies
|
US7150992B1
(en)
|
1995-10-04 |
2006-12-19 |
Innunex Corporation |
Methods of preparing dendritic cells with flt3-ligand and antigen
|
US7361330B2
(en)
*
|
1995-10-04 |
2008-04-22 |
Immunex Corporation |
Methods of using flt3-ligand in the treatment of fibrosarcoma
|
US20020034517A1
(en)
*
|
1995-10-04 |
2002-03-21 |
Kenneth Brasel |
Dendritic cell stimulatory factor
|
US6936439B2
(en)
*
|
1995-11-22 |
2005-08-30 |
Amgen Inc. |
OB fusion protein compositions and methods
|
US20030040467A1
(en)
*
|
1998-06-15 |
2003-02-27 |
Mary Ann Pelleymounter |
Ig/ob fusions and uses thereof.
|
US20030026779A1
(en)
*
|
1999-10-15 |
2003-02-06 |
Liming Yu |
Treatment of tumors and viral infections with a hybrid conjugate of interferon and an immunoglobulin Fc
|
GB9526733D0
(en)
*
|
1995-12-30 |
1996-02-28 |
Delta Biotechnology Ltd |
Fusion proteins
|
WO1997025425A1
(en)
|
1996-01-08 |
1997-07-17 |
Genentech, Inc. |
Wsx receptor and ligands
|
US6750334B1
(en)
|
1996-02-02 |
2004-06-15 |
Repligen Corporation |
CTLA4-immunoglobulin fusion proteins having modified effector functions and uses therefor
|
US5917026A
(en)
*
|
1996-02-05 |
1999-06-29 |
Loewenadler; Bjoern |
Fusion proteins of immunopotentiating activity
|
NZ331163A
(en)
|
1996-02-09 |
2000-07-28 |
Amgen Inc |
Composition comprising interleukin-1 inhibitor and hydrogel ester (hyaluronan) for treating inflammatory diseases
|
CZ291212B6
(cs)
*
|
1996-02-20 |
2003-01-15 |
Applied Research Systems Ars Holding N. V. |
Hybridní protein, molekula DNA, expresní vektor, hostitelská buňka, způsob produkce hybridního proteinu, jeho pouľití a farmaceutický prostředek
|
US6194177B1
(en)
*
|
1996-02-20 |
2001-02-27 |
Applied Research Systems Ars Holding N.V. |
DNA encoding a hybrid heterodimeric protein
|
GB9604518D0
(en)
*
|
1996-03-02 |
1996-05-01 |
Smithkline Beecham Plc |
Novel compounds
|
US6458354B1
(en)
|
1996-03-28 |
2002-10-01 |
The Johns Hopkins University |
Molecular complexes which modify immune responses
|
US6015884A
(en)
*
|
1996-03-28 |
2000-01-18 |
The Johns Hopkins University |
Soluble divalent and multivalent heterodimeric analogs of proteins
|
US7026116B1
(en)
*
|
1996-04-04 |
2006-04-11 |
Bio-Rad Laboratories, Inc. |
Polymorphisms in the region of the human hemochromatosis gene
|
US6140305A
(en)
*
|
1996-04-04 |
2000-10-31 |
Bio-Rad Laboratories, Inc. |
Hereditary hemochromatosis gene products
|
US7063965B2
(en)
*
|
1996-04-05 |
2006-06-20 |
Regeneron Pharmaceuticals, Inc. |
Nucleic acid encoding TIE-2 ligand
|
US6060054A
(en)
*
|
1996-04-10 |
2000-05-09 |
National Jewish Medical And Research Center |
Product for T lymphocyte immunosuppression
|
US6117977A
(en)
*
|
1996-04-24 |
2000-09-12 |
Genentech, Inc. |
Type C lectins
|
US6451308B1
(en)
*
|
1996-04-26 |
2002-09-17 |
Beth Israel Deaconess Medical Center |
Antagonists of interleukin-15
|
ES2243995T3
(es)
*
|
1996-04-26 |
2005-12-01 |
Beth Israel Deaconess Medical Center, Inc. |
Antagonistas de interleucina-15.
|
ATE299936T1
(de)
*
|
1996-05-02 |
2005-08-15 |
Mochida Pharm Co Ltd |
Fas antigen-derivate
|
US6100071A
(en)
|
1996-05-07 |
2000-08-08 |
Genentech, Inc. |
Receptors as novel inhibitors of vascular endothelial growth factor activity and processes for their production
|
US6849399B1
(en)
|
1996-05-23 |
2005-02-01 |
Bio-Rad Laboratories, Inc. |
Methods and compositions for diagnosis and treatment of iron misregulation diseases
|
TW555765B
(en)
*
|
1996-07-09 |
2003-10-01 |
Amgen Inc |
Low molecular weight soluble tumor necrosis factor type-I and type-II proteins
|
DK0912734T3
(da)
|
1996-07-12 |
2011-02-07 |
Genentech Inc |
Kimæriske heteromultimer-adhæsiner
|
AU727606B2
(en)
*
|
1996-07-12 |
2000-12-14 |
Genentech Inc. |
Gamma-heregulin
|
US6159462A
(en)
*
|
1996-08-16 |
2000-12-12 |
Genentech, Inc. |
Uses of Wnt polypeptides
|
US5851984A
(en)
*
|
1996-08-16 |
1998-12-22 |
Genentech, Inc. |
Method of enhancing proliferation or differentiation of hematopoietic stem cells using Wnt polypeptides
|
ATE247974T1
(de)
|
1996-12-06 |
2003-09-15 |
Amgen Inc |
Kombinationtherapie mit einem tnf-bindendem protein zür behandlung von durch tnf verursachten erkrangungen
|
EP2002846B1
(de)
|
1996-12-06 |
2017-01-25 |
Amgen Inc. |
Kombinationstherapie mit einem IL-1-Inhibitor zur Behandlung von IL-1-vermittelten Krankheiten
|
CA2279547A1
(en)
*
|
1997-01-31 |
1998-08-06 |
University Of Rochester |
Chimeric antibody fusion proteins for the recruitment and stimulation of an antitumor immune response
|
US6268411B1
(en)
*
|
1997-09-11 |
2001-07-31 |
The Johns Hopkins University |
Use of multivalent chimeric peptide-loaded, MHC/ig molecules to detect, activate or suppress antigen-specific T cell-dependent immune responses
|
US7435793B2
(en)
*
|
1998-05-15 |
2008-10-14 |
Genentech, Inc. |
Peptides that induce chondrocyte redifferentiation
|
US20020137890A1
(en)
*
|
1997-03-31 |
2002-09-26 |
Genentech, Inc. |
Secreted and transmembrane polypeptides and nucleic acids encoding the same
|
ATE505543T1
(de)
|
1997-04-16 |
2011-04-15 |
Millennium Pharm Inc |
Zusammensetzung, umfassend einen antikörper, der selektiv an ein cysteinreiches sekretiertes protein (crsp) bindet
|
US6190909B1
(en)
*
|
1997-04-17 |
2001-02-20 |
Millennium Pharmaceuticals, Inc. |
TH2-specific gene
|
EP0980432A1
(de)
*
|
1997-05-01 |
2000-02-23 |
Amgen, Inc. |
Chimäre opg-polypeptide.
|
DK0979281T3
(da)
|
1997-05-02 |
2005-11-21 |
Genentech Inc |
Fremgangsmåde til fremstilling af multispecifikke antistoffer med heteromultimere og fælles bestanddele
|
US7951917B1
(en)
*
|
1997-05-02 |
2011-05-31 |
Genentech, Inc. |
Method for making multispecific antibodies having heteromultimeric and common components
|
US20030207346A1
(en)
*
|
1997-05-02 |
2003-11-06 |
William R. Arathoon |
Method for making multispecific antibodies having heteromultimeric and common components
|
US20020062010A1
(en)
*
|
1997-05-02 |
2002-05-23 |
Genentech, Inc. |
Method for making multispecific antibodies having heteromultimeric and common components
|
CA2293808C
(en)
|
1997-06-13 |
2006-10-17 |
Progenitor, Inc. |
Methods and compositions for diagnosis and treatment of iron overload diseases and iron deficiency diseases
|
US20030073809A1
(en)
*
|
1997-06-16 |
2003-04-17 |
Genentech, Inc. |
Secreted and transmembrane polypeptides and nucleic acids encoding the same
|
US20040191256A1
(en)
*
|
1997-06-24 |
2004-09-30 |
Genentech, Inc. |
Methods and compositions for galactosylated glycoproteins
|
KR100220645B1
(ko)
*
|
1997-07-04 |
1999-09-15 |
구광시 |
벤젠유도체의 제조방법
|
US6187564B1
(en)
|
1997-07-10 |
2001-02-13 |
Beth Israel Deaconess Medical Center |
DNA encoding erythropoietin multimers having modified 5′ and 3′ sequences and its use to prepare EPO therapeutics
|
US6165476A
(en)
*
|
1997-07-10 |
2000-12-26 |
Beth Israel Deaconess Medical Center |
Fusion proteins with an immunoglobulin hinge region linker
|
US6242570B1
(en)
|
1997-07-10 |
2001-06-05 |
Beth Israel Deaconess Medical Center |
Production and use of recombinant protein multimers with increased biological activity
|
US20030166108A1
(en)
*
|
1997-09-18 |
2003-09-04 |
Genentech, Inc. |
Secreted and transmembrane polypeptides and nucleic acids encoding the same
|
US6391311B1
(en)
*
|
1998-03-17 |
2002-05-21 |
Genentech, Inc. |
Polypeptides having homology to vascular endothelial cell growth factor and bone morphogenetic protein 1
|
US6503184B1
(en)
|
1997-10-21 |
2003-01-07 |
Human Genome Sciences, Inc. |
Human tumor necrosis factor receptor-like proteins TR11, TR11SV1 and TR11SV2
|
US6509173B1
(en)
*
|
1997-10-21 |
2003-01-21 |
Human Genome Sciences, Inc. |
Human tumor necrosis factor receptor-like proteins TR11, TR11SV1, and TR11SV2
|
US6689607B2
(en)
|
1997-10-21 |
2004-02-10 |
Human Genome Sciences, Inc. |
Human tumor, necrosis factor receptor-like proteins TR11, TR11SV1 and TR11SV2
|
US20040136986A1
(en)
*
|
1997-10-31 |
2004-07-15 |
Genentech, Inc. |
Methods and compositions comprising glycoprotein glycoforms
|
US6576743B1
(en)
*
|
1997-11-26 |
2003-06-10 |
Zymogenetics, Inc. |
Mammalian cytokine-like polypeptide-10
|
WO1999029732A2
(en)
|
1997-12-08 |
1999-06-17 |
Lexigen Pharmaceuticals Corporation |
Heterodimeric fusion proteins useful for targeted immune therapy and general immune stimulation
|
US6207413B1
(en)
*
|
1998-01-22 |
2001-03-27 |
Regeneron Pharmaceuticals, Inc. |
Nucleic acids encoding novel orphan cytokine receptors
|
US20030105294A1
(en)
*
|
1998-02-25 |
2003-06-05 |
Stephen Gillies |
Enhancing the circulating half life of antibody-based fusion proteins
|
US7189400B2
(en)
*
|
1998-03-17 |
2007-03-13 |
Genetics Institute, Llc |
Methods of treatment with antagonists of MU-1
|
US6057128A
(en)
|
1998-03-17 |
2000-05-02 |
Genetics Institute, Inc. |
MU-1, member of the cytokine receptor family
|
US7198789B2
(en)
*
|
1998-03-17 |
2007-04-03 |
Genetics Institute, Llc |
Methods and compositions for modulating interleukin-21 receptor activity
|
US7723488B2
(en)
*
|
1998-03-27 |
2010-05-25 |
Genentech, Inc. |
Monoclonal antibodies to secreted and transmembrane polypeptides
|
US7371836B2
(en)
*
|
1998-03-27 |
2008-05-13 |
Genentech, Inc. |
PRO526 nucleic acids
|
JP2002511432A
(ja)
*
|
1998-04-15 |
2002-04-16 |
レキシジェン ファーマシューティカルズ コーポレイション |
新脈管形成インヒビターの同時投与による抗体−サイトカイン融合タンパク質媒介性免疫応答の増強
|
PT1076703E
(pt)
*
|
1998-05-15 |
2007-10-10 |
Genentech Inc |
''utilizações terapêuticas de polipéptido homólogos de il-17''
|
US20030134327A1
(en)
*
|
1998-05-15 |
2003-07-17 |
Genentech, Inc. |
Secreted and transmembrane polypeptides and nucleic acids encoding the same
|
CA2328498A1
(en)
|
1998-06-12 |
1999-12-16 |
Genentech, Inc. |
Monoclonal antibodies, cross-reactive antibodies and method for producing the same____________________________________
|
DK1088084T3
(da)
*
|
1998-06-15 |
2007-01-29 |
Gtc Biotherapeutics Inc |
Erythropoietin analog-humant serumalbumin fusionsprotein
|
US20050181482A1
(en)
*
|
2004-02-12 |
2005-08-18 |
Meade Harry M. |
Method for the production of an erythropoietin analog-human IgG fusion proteins in transgenic mammal milk
|
US20030065154A1
(en)
*
|
2000-03-30 |
2003-04-03 |
Genentech, Inc. |
Interleukin-8 homologous polypeptides and therapeutic uses thereof
|
US20070003545A9
(en)
*
|
1999-06-02 |
2007-01-04 |
Eaton Dan L |
Interleukin-8 homologous polypeptides and therapeutic uses thereof
|
US7339033B2
(en)
*
|
1998-06-26 |
2008-03-04 |
Genentech, Inc. |
Pro1481
|
US20020099197A1
(en)
*
|
1998-07-21 |
2002-07-25 |
Rory A.J. Curtis |
Novel potassium channel molecules and uses therefor
|
AU764020B2
(en)
*
|
1998-08-31 |
2003-08-07 |
Biogen Idec Ma Inc. |
Method of modulating memory effector T-cells and compositions
|
SK287918B6
(sk)
|
1998-10-16 |
2012-03-02 |
Biogen Idec Ma Inc. |
Composition containing glycosylated interferon-beta-1a, pharmaceutical composition, use of composition, in-vitro method of prolonging the activity of interferon-beta-1a and use of polymer moiety
|
SK287491B6
(sk)
*
|
1998-10-16 |
2010-11-08 |
Biogen Idec Ma Inc. |
Fúzne proteíny interferónu- beta-1a a ich použitie
|
US6660843B1
(en)
|
1998-10-23 |
2003-12-09 |
Amgen Inc. |
Modified peptides as therapeutic agents
|
EP1124961B9
(de)
|
1998-10-23 |
2010-07-21 |
Kirin-Amgen Inc. |
Thrombopoietin substitute
|
US7488590B2
(en)
|
1998-10-23 |
2009-02-10 |
Amgen Inc. |
Modified peptides as therapeutic agents
|
WO2000027885A1
(fr)
*
|
1998-11-05 |
2000-05-18 |
Kyowa Hakko Kogyo Co., Ltd. |
Nouveau popypeptide chimerique
|
EP1129193A4
(de)
*
|
1998-11-10 |
2005-08-10 |
Human Genome Sciences Inc |
Chemokin beta-7
|
US7294482B2
(en)
*
|
1998-11-19 |
2007-11-13 |
Millennium Pharmaceuticals, Inc. |
EGF-like nucleic acids
|
US7235642B1
(en)
*
|
1999-01-12 |
2007-06-26 |
Genentech, Inc. |
Anti-PRO 1313 antibodies
|
US6656728B1
(en)
|
1999-02-08 |
2003-12-02 |
Chiron Corporation |
Fibroblast growth factor receptor-immunoglobulin fusion
|
WO2000056363A1
(en)
|
1999-03-19 |
2000-09-28 |
Genentech, Inc. |
Treatment of lfa-1 associated disorders with increasing doses of lfa-1 antagonist
|
US7011833B1
(en)
*
|
1999-05-06 |
2006-03-14 |
Genetics Institute, Inc. |
Enhancing immune responses with B7-1 or B7-2 in the absence of a crosslinking agent
|
US20050079577A1
(en)
*
|
1999-05-14 |
2005-04-14 |
Ashkenazi Avi J. |
Secreted and transmembrane polypeptides and nucleic acids encoding the same
|
PL352332A1
(en)
*
|
1999-05-19 |
2003-08-11 |
Lexigen Pharm Corp |
Expression and export of interferon-alpha proteins as fc fusion proteins
|
IL146842A0
(en)
*
|
1999-06-01 |
2002-07-25 |
Biogen Inc |
Polymer conjugates of hedgehog proteins and uses
|
WO2000073498A1
(en)
*
|
1999-06-02 |
2000-12-07 |
Millennium Pharmaceuticals, Inc. |
Compositions and methods for the treatment and diagnosis of immune disorders
|
US6924359B1
(en)
*
|
1999-07-01 |
2005-08-02 |
Yale University |
Neovascular-targeted immunoconjugates
|
DE60028970T2
(de)
|
1999-07-02 |
2007-02-15 |
Genentech Inc., San Francisco |
An her2 bindende peptidverbindungen
|
CA2373735A1
(en)
*
|
1999-07-02 |
2001-01-11 |
Genentech, Inc. |
Fviia antagonists
|
US7011967B1
(en)
*
|
1999-07-12 |
2006-03-14 |
Merck Patent Gmbh |
Seripancrin
|
SK782002A3
(en)
*
|
1999-07-21 |
2003-08-05 |
Lexigen Pharm Corp |
FC fusion proteins for enhancing the immunogenicity of protein and peptide antigens
|
US7067110B1
(en)
|
1999-07-21 |
2006-06-27 |
Emd Lexigen Research Center Corp. |
Fc fusion proteins for enhancing the immunogenicity of protein and peptide antigens
|
AU6607100A
(en)
*
|
1999-07-23 |
2001-02-13 |
Regents Of The University Of California, The |
Anti-growth factor receptor avidin fusion proteins as universal vectors for drugdelivery
|
JP2003512303A
(ja)
*
|
1999-08-06 |
2003-04-02 |
ジェネンテック・インコーポレーテッド |
因子viiaのペプチドアンタゴニスト
|
CN1235911C
(zh)
*
|
1999-08-09 |
2006-01-11 |
利思进药品公司 |
多细胞因子-抗体复合物
|
HU228477B1
(en)
|
1999-08-23 |
2013-03-28 |
Dana Farber Cancer Inst Inc |
Pd-1, a receptor for b7-4, and uses therefor
|
US20030166858A1
(en)
*
|
1999-09-16 |
2003-09-04 |
Samuel Davis |
TIE-2 ligands, methods of making and uses thereof
|
US6323334B1
(en)
*
|
1999-09-24 |
2001-11-27 |
Millennium Pharmaceuticals, Inc. |
Nucleic acid molecules encoding a 103 gene product and uses therefor
|
AU780693B2
(en)
*
|
1999-11-05 |
2005-04-14 |
Curis, Inc. |
Hedgehog fusion proteins and uses
|
US20050202538A1
(en)
*
|
1999-11-12 |
2005-09-15 |
Merck Patent Gmbh |
Fc-erythropoietin fusion protein with improved pharmacokinetics
|
EP1228214A2
(de)
|
1999-11-12 |
2002-08-07 |
MERCK PATENT GmbH |
Erythropoietinformen mit verbesserten eigenschaften
|
US6610286B2
(en)
|
1999-12-23 |
2003-08-26 |
Zymogenetics, Inc. |
Method for treating inflammation using soluble receptors to interleukin-20
|
US7122632B2
(en)
*
|
1999-12-23 |
2006-10-17 |
Zymogenetics, Inc. |
Soluble Interleukin-20 receptor
|
US7307153B2
(en)
*
|
1999-12-23 |
2007-12-11 |
Genentech, Inc. |
Antibodies that bind PRO9912
|
US7164001B2
(en)
*
|
2000-01-20 |
2007-01-16 |
Genentech, Inc. |
Compositions and methods for the treatment of immune related diseases
|
DK1252192T3
(da)
|
2000-02-11 |
2006-11-20 |
Merck Patent Gmbh |
Forbedring af antistofbaserede fusionsproteiners serumhalveringstid
|
KR20070057282A
(ko)
*
|
2000-02-21 |
2007-06-04 |
어플라이드 리서치 시스템스 에이알에스 홀딩 엔.브이. |
Il-18 저해물질의 용도
|
US7541184B2
(en)
*
|
2000-02-24 |
2009-06-02 |
Invitrogen Corporation |
Activation and expansion of cells
|
US7572631B2
(en)
*
|
2000-02-24 |
2009-08-11 |
Invitrogen Corporation |
Activation and expansion of T cells
|
US20060073547A1
(en)
*
|
2000-03-01 |
2006-04-06 |
Genentech, Inc. |
Secreted and transmembrane polypeptides and nucleic acids encoding the same
|
US6984519B2
(en)
|
2000-03-01 |
2006-01-10 |
Genetech, Inc. |
Nucleic acids encoding peptides that induce chondrocyte redifferentiation
|
US20060002943A1
(en)
*
|
2000-03-02 |
2006-01-05 |
Genentech, Inc. |
Compositions and methods for the treatment of tumor of hematopoietic origin
|
US20020064820A1
(en)
*
|
2000-03-13 |
2002-05-30 |
Jean-Michel Dayer |
Apo-A-I regulation of T-cell signaling
|
US7514239B2
(en)
*
|
2000-03-28 |
2009-04-07 |
Amgen Inc. |
Nucleic acid molecules encoding beta-like glycoprotein hormone polypeptides and heterodimers thereof
|
EP1272635A1
(de)
*
|
2000-04-10 |
2003-01-08 |
MERCK PATENT GmbH |
Cryptic-ähnliches sekretiertes protein
|
US20050100991A1
(en)
*
|
2001-04-12 |
2005-05-12 |
Human Genome Sciences, Inc. |
Albumin fusion proteins
|
EP1832599A3
(de)
*
|
2000-04-12 |
2007-11-21 |
Human Genome Sciences, Inc. |
Albuminfusionsproteine
|
US6946134B1
(en)
|
2000-04-12 |
2005-09-20 |
Human Genome Sciences, Inc. |
Albumin fusion proteins
|
KR20030016250A
(ko)
*
|
2000-04-25 |
2003-02-26 |
아이덱 파마슈티칼즈 코포레이션 |
중추신경계 림프종 치료용 리툭시맵의 초내 투여
|
US6756480B2
(en)
|
2000-04-27 |
2004-06-29 |
Amgen Inc. |
Modulators of receptors for parathyroid hormone and parathyroid hormone-related protein
|
ES2332872T3
(es)
*
|
2000-04-28 |
2010-02-15 |
Planet Biotechnology, Inc. |
Inmunoadhesina para la prevencion de la infeccion por rinovirus.
|
US20060015969A1
(en)
*
|
2000-04-28 |
2006-01-19 |
Planet Biotechnology, Inc. |
Novel immunoadhesins for treating and prventing toxicity and pathogen-mediated diseases
|
CA2407956A1
(en)
*
|
2000-05-03 |
2001-11-08 |
Amgen Inc. |
Modified peptides as therapeutic agents
|
US20020102232A1
(en)
*
|
2000-05-11 |
2002-08-01 |
Chang Tse W. |
Compositions and methods for induction of active autoimmunity
|
AU2001261585B2
(en)
*
|
2000-05-12 |
2006-08-31 |
Beth Israel Deaconess Medical Center, Inc. |
Compositions and methods for achieving immune suppression
|
EP1714661A3
(de)
|
2000-05-19 |
2012-03-14 |
The Center for Blood Research, INC. |
Verfahren zur Diagnose und Behandlung von hämostatischen Störungen durch Modulation der P-Selectin Aktivität
|
US20040034193A1
(en)
*
|
2001-06-13 |
2004-02-19 |
Samy Ashkar |
Biosynthetic oncolytic molecules and uses therefor
|
US20050048614A1
(en)
*
|
2000-06-13 |
2005-03-03 |
Children's Medical Center Corporation |
Biosynthetic oncolytic molecules and uses therefor
|
ES2593002T3
(es)
*
|
2000-06-26 |
2016-12-05 |
Zymogenetics, Inc. |
Receptor ZCYTOR17 de citocina
|
US20030096339A1
(en)
*
|
2000-06-26 |
2003-05-22 |
Sprecher Cindy A. |
Cytokine receptor zcytor17
|
NZ522844A
(en)
|
2000-06-28 |
2005-02-25 |
Brigham & Womens Hospital |
PD-L2 molecules: novel PD-1 ligands and methods to identify compounds to modulate T cell activation
|
ES2288967T3
(es)
*
|
2000-06-29 |
2008-02-01 |
Merck Patent Gmbh |
Reforzamiento de las respuestas inmunes mediadas por la proteina de fusion anticuerpo-citoquina por medio del tratamiento combinado por agentes que mejoran la incorporacion de inmunocitoquina.
|
UA81743C2
(uk)
|
2000-08-07 |
2008-02-11 |
Центокор, Инк. |
МОНОКЛОНАЛЬНЕ АНТИТІЛО ЛЮДИНИ, ЩО СПЕЦИФІЧНО ЗВ'ЯЗУЄТЬСЯ З ФАКТОРОМ НЕКРОЗУ ПУХЛИН АЛЬФА (ФНПα), ФАРМАЦЕВТИЧНА КОМПОЗИЦІЯ, ЩО ЙОГО МІСТИТЬ, ТА СПОСІБ ЛІКУВАННЯ РЕВМАТОЇДНОГО АРТРИТУ
|
US7288390B2
(en)
|
2000-08-07 |
2007-10-30 |
Centocor, Inc. |
Anti-dual integrin antibodies, compositions, methods and uses
|
US6902734B2
(en)
|
2000-08-07 |
2005-06-07 |
Centocor, Inc. |
Anti-IL-12 antibodies and compositions thereof
|
CA2418950A1
(en)
*
|
2000-08-08 |
2002-02-14 |
Zymogenetics, Inc. |
Soluble zcytor 11 cytokine receptors
|
US20030215916A1
(en)
*
|
2000-08-18 |
2003-11-20 |
Feder John N. |
Novel imidazoline receptor homologs
|
EP1315812B1
(de)
|
2000-09-01 |
2009-11-11 |
The Center for Blood Research, INC. |
Veränderte, in gewünschter konformation stabilisierte polypeptide und verfahren zu deren herstellung
|
US20020119148A1
(en)
|
2000-09-01 |
2002-08-29 |
Gerritsen Mary E. |
ErbB4 antagonists
|
EP2123672A1
(de)
*
|
2000-09-14 |
2009-11-25 |
Beth Israel Deaconess Medical Center, Inc. |
Modulation von IL-2- und IL-15-vermittelten T-Zellantworten
|
AU2002214545B2
(en)
|
2000-09-26 |
2008-04-03 |
Genentech, Inc. |
IGE receptor antagonists
|
WO2002026986A2
(en)
*
|
2000-09-29 |
2002-04-04 |
Bristol-Myers Squibb Company |
Identification and cloning of a full-length human cink-related gene, mist (mast cell immunoreceptor signal transducer)
|
US20030211549A1
(en)
*
|
2000-10-06 |
2003-11-13 |
Murphy Andrew J. |
Functional proteins and therapeutic and diagnostic methods for use thereof
|
EP1364019A2
(de)
*
|
2000-11-07 |
2003-11-26 |
Board of Regents, The University of Texas System |
Verfahren und zusammensetzungen bezogen auf muskelnspezifischen sarkomerischen calcineurinbindungsproteine (calsarine)
|
EP1349568B1
(de)
*
|
2000-12-04 |
2009-09-16 |
Auckland Uniservices Limited |
Immunmodulatorische konstruktionen und ihre verwendung
|
US20040253242A1
(en)
*
|
2000-12-05 |
2004-12-16 |
Bowdish Katherine S. |
Rationally designed antibodies
|
US7396917B2
(en)
*
|
2000-12-05 |
2008-07-08 |
Alexion Pharmaceuticals, Inc. |
Rationally designed antibodies
|
PT1642910E
(pt)
*
|
2000-12-05 |
2012-03-22 |
Alexion Pharma Inc |
Anticorpos concebidos de modo racional
|
CA2438386A1
(en)
*
|
2001-02-16 |
2002-08-29 |
Bristol-Myers Squibb Company |
Polynucleotides encoding a novel glycine receptor alpha subunit expressed in the gastrointestinal tract, hgra4, and splice variant thereof
|
MXPA03008031A
(es)
*
|
2001-03-07 |
2003-12-04 |
Merck Patent Gmbh |
Tecnologia de expresion para proteinas que contienen porcion de anticuerpo isotipo hibrida.
|
US8163289B2
(en)
|
2001-03-09 |
2012-04-24 |
Iterative Therapeutics, Inc. |
Methods and compositions involving polymeric immunoglobulin fusion proteins
|
EP1395605B8
(de)
|
2001-03-09 |
2014-12-17 |
Iterative Therapeutics, Inc. |
Polymere immunoglobulin-fusionsproteine, die auf fc-gamma-rezeptoren mit geringer affinität zielen
|
US6992174B2
(en)
|
2001-03-30 |
2006-01-31 |
Emd Lexigen Research Center Corp. |
Reducing the immunogenicity of fusion proteins
|
NZ528265A
(en)
|
2001-04-02 |
2005-10-28 |
Wyeth Corp |
Screening of compounds which modulate PD-1 signalling by testing for compounds that modulate phosphorylation of SHP-2, ERK1 or ERK-2, and PKC-theta
|
US20050054051A1
(en)
*
|
2001-04-12 |
2005-03-10 |
Human Genome Sciences, Inc. |
Albumin fusion proteins
|
US7507413B2
(en)
|
2001-04-12 |
2009-03-24 |
Human Genome Sciences, Inc. |
Albumin fusion proteins
|
US20050244931A1
(en)
*
|
2001-04-12 |
2005-11-03 |
Human Genome Sciences, Inc. |
Albumin fusion proteins
|
US20060084794A1
(en)
*
|
2001-04-12 |
2006-04-20 |
Human Genome Sciences, Inc. |
Albumin fusion proteins
|
ITRE20010042A1
(it)
*
|
2001-04-24 |
2002-10-24 |
Corghi Spa |
Dispositivo sollevatore per macchine smontagomme
|
US20050089932A1
(en)
*
|
2001-04-26 |
2005-04-28 |
Avidia Research Institute |
Novel proteins with targeted binding
|
US7265208B2
(en)
|
2001-05-01 |
2007-09-04 |
The Regents Of The University Of California |
Fusion molecules and treatment of IgE-mediated allergic diseases
|
US6969517B2
(en)
|
2001-05-03 |
2005-11-29 |
Emd Lexigen Research Center Corp. |
Recombinant tumor specific antibody and use thereof
|
AU2002342669C1
(en)
|
2001-05-11 |
2010-10-07 |
Amgen, Inc. |
Peptides and related molecules that bind to TALL-1
|
US20100056762A1
(en)
|
2001-05-11 |
2010-03-04 |
Old Lloyd J |
Specific binding proteins and uses thereof
|
WO2002102320A2
(en)
*
|
2001-06-15 |
2002-12-27 |
Tanox, Inc. |
Fce fusion proteins for treatment of allergy and asthma
|
WO2004058821A2
(en)
*
|
2002-12-27 |
2004-07-15 |
Domantis Limited |
Dual specific single domain antibodies specific for a ligand and for the receptor of the ligand
|
US20060073141A1
(en)
*
|
2001-06-28 |
2006-04-06 |
Domantis Limited |
Compositions and methods for treating inflammatory disorders
|
AU2002320352A1
(en)
*
|
2001-07-24 |
2003-02-17 |
Biogen Idec Ma Inc. |
Methods for treating or preventing sclerotic disorders using cd2-binding agents
|
AU2002355955A1
(en)
*
|
2001-08-13 |
2003-03-03 |
University Of Southern California |
Interleukin-2 mutants with reduced toxicity
|
US6900292B2
(en)
*
|
2001-08-17 |
2005-05-31 |
Lee-Hwei K. Sun |
Fc fusion proteins of human erythropoietin with increased biological activities
|
ATE557092T1
(de)
|
2001-08-29 |
2012-05-15 |
Genentech Inc |
Bv8-nukleinsäuren und polypeptide mit mitogener aktivität
|
MXPA04001804A
(es)
*
|
2001-08-30 |
2005-03-07 |
Biorexis Pharmaceutical Corp |
Proteinas de fusion de transferrina modificada.
|
US6797493B2
(en)
|
2001-10-01 |
2004-09-28 |
Lee-Hwei K. Sun |
Fc fusion proteins of human granulocyte colony-stimulating factor with increased biological activities
|
AU2002332041A1
(en)
*
|
2001-10-05 |
2003-04-22 |
Human Genome Sciences, Inc. |
Albumin fusion proteins
|
US7138370B2
(en)
*
|
2001-10-11 |
2006-11-21 |
Amgen Inc. |
Specific binding agents of human angiopoietin-2
|
US7205275B2
(en)
*
|
2001-10-11 |
2007-04-17 |
Amgen Inc. |
Methods of treatment using specific binding agents of human angiopoietin-2
|
JP2005506073A
(ja)
*
|
2001-10-19 |
2005-03-03 |
ザイモジェネティクス,インコーポレイティド |
二量体化された成長因子及びそれを生成するための材料及び方法
|
ATE473015T1
(de)
*
|
2001-10-25 |
2010-07-15 |
Government Of The Us Secretary |
Effiziente hemmung des eintritts von hiv-1-virus durch ein neues fusionsprotein mit cd4
|
US20070118934A1
(en)
*
|
2001-10-26 |
2007-05-24 |
Planet Biotechnology, Inc. |
Chimeric toxin receptor proteins and chimeric toxin receptor proteins for treatment and prevention of anthrax
|
ES2381025T3
(es)
*
|
2001-12-04 |
2012-05-22 |
Merck Patent Gmbh |
Inmunocitocinas con selectividad modulada
|
US7858297B2
(en)
*
|
2001-12-18 |
2010-12-28 |
Centre National De La Recherche Scientifique Cnrs |
Chemokine-binding protein and methods of use
|
AU2002361385B2
(en)
*
|
2001-12-18 |
2009-11-19 |
Centre National De La Recherche Scientifique Cnrs |
Novel death associated proteins of the THAP family and related Par4 pathways involved in apoptosis control
|
DK1463751T3
(da)
|
2001-12-21 |
2013-08-26 |
Human Genome Sciences Inc |
Albuminfusionsproteiner.
|
KR101271635B1
(ko)
*
|
2001-12-21 |
2013-06-12 |
휴먼 게놈 사이언시즈, 인코포레이티드 |
알부민 융합 단백질
|
AU2002364587A1
(en)
*
|
2001-12-21 |
2003-07-30 |
Human Genome Sciences, Inc. |
Albumin fusion proteins
|
ATE401390T1
(de)
|
2002-01-18 |
2008-08-15 |
Zymogenetics Inc |
Zytokin (zcytor17-ligand)
|
UA82184C2
(uk)
|
2002-01-18 |
2008-03-25 |
Байоджин Айдек Ма Инк. |
Поліалкіленгліколь з залишком для кон'югації біологічно активної сполуки
|
US7164002B2
(en)
|
2002-02-06 |
2007-01-16 |
Genentech, Inc. |
FVIIa antagonists
|
US20030211470A1
(en)
*
|
2002-03-15 |
2003-11-13 |
Olson William C. |
CD4-IgG2-based salvage therapy of HIV-1 infection
|
KR20040101426A
(ko)
*
|
2002-04-10 |
2004-12-02 |
어플라이드 리서치 시스템스 에이알에스 홀딩 엔.브이. |
신규한 mcp 단백질의 길항제
|
US20040016010A1
(en)
*
|
2002-04-17 |
2004-01-22 |
Marion Kasaian |
IL-21 receptor knockout animal and methods of use thereof
|
AU2003241818A1
(en)
|
2002-05-29 |
2003-12-12 |
Yamasa Corporation |
Novel polyphosphate:amp phosphotransferase
|
DE60334453D1
(de)
*
|
2002-05-30 |
2010-11-18 |
Macrogenics Inc |
Cd16a bindungsproteine und verwendung zur behandlung von immunkrankheiten
|
NZ519371A
(en)
*
|
2002-06-04 |
2004-11-26 |
Auckland Uniservices Ltd |
Immunomodulatory constructs and their uses
|
US20070071744A1
(en)
*
|
2002-06-07 |
2007-03-29 |
Gotz Munch |
Agents which bind to epitopes of glycoprotein VI
|
EP1369128A1
(de)
*
|
2002-06-07 |
2003-12-10 |
Procorde GmbH |
Glycoprotein VI Inhibitoren und deren therapeutische Verwendung
|
US20090130021A1
(en)
*
|
2002-06-07 |
2009-05-21 |
Gotz Munch |
Methods, products and uses involving platelets and/or the vasculature
|
US7531178B2
(en)
*
|
2002-06-07 |
2009-05-12 |
Trigen Gmbh |
Immunoadhesin comprising a glycoprotein VI domain
|
US8029803B2
(en)
|
2002-06-20 |
2011-10-04 |
Paladin Labs, Inc. |
Chimeric antigens for eliciting an immune response
|
US8025873B2
(en)
|
2002-06-20 |
2011-09-27 |
Paladin Labs, Inc. |
Chimeric antigens for eliciting an immune response
|
CA2490409A1
(en)
|
2002-06-28 |
2004-01-08 |
Centocor, Inc. |
Mammalian ch1 deleted mimetibodies, compositions, methods and uses
|
US20070104710A1
(en)
*
|
2002-06-28 |
2007-05-10 |
Domants Limited |
Ligand that has binding specificity for IL-4 and/or IL-13
|
CN1678634A
(zh)
*
|
2002-06-28 |
2005-10-05 |
多曼蒂斯有限公司 |
免疫球蛋白单个变体抗原结合区及其特异性构建体
|
CN1241946C
(zh)
*
|
2002-07-01 |
2006-02-15 |
美国福源集团 |
对多种细胞具刺激增生作用的人血清白蛋白重组融合蛋白
|
EP1551449B1
(de)
*
|
2002-07-12 |
2010-10-06 |
The Johns Hopkins University |
Reagenzien und verfahren zum eingriff in einzigartige klonotype lymphozyten-rezeptoren
|
ZA200500480B
(en)
|
2002-07-15 |
2006-10-25 |
Wyeth Corp |
Methods and compositions for modulating T helper (TH) cell development and function
|
US20040110681A1
(en)
*
|
2002-08-08 |
2004-06-10 |
Xiao-Min Fan |
Method to identify targeting molecules
|
PL376536A1
(pl)
|
2002-08-28 |
2006-01-09 |
Immunex Corporation |
Kompozycje i sposoby leczenia chorób układu sercowo-naczyniowego
|
DE10251463A1
(de)
*
|
2002-11-05 |
2004-05-19 |
BSH Bosch und Siemens Hausgeräte GmbH |
Elektrisch angetriebene Pumpe
|
US20050054054A1
(en)
*
|
2002-11-12 |
2005-03-10 |
Foss Francine M. |
Interleukin-7 molecules with altered biological properties
|
PT1572748E
(pt)
*
|
2002-12-17 |
2010-09-28 |
Merck Patent Gmbh |
Anticorpo humanizado (h14.18) do anticorpo 14.18 de rato que se liga ao gd2 e a sua fusão com a il-2
|
US20110223168A1
(en)
*
|
2002-12-27 |
2011-09-15 |
Greg Winter |
Ligand that has binding specificity for il-4 and/or il-13
|
GB0230203D0
(en)
*
|
2002-12-27 |
2003-02-05 |
Domantis Ltd |
Fc fusion
|
WO2004062619A2
(en)
*
|
2003-01-13 |
2004-07-29 |
Macrogenics, Inc. |
SOLUBLE FcϜR FUSION PROTEINS AND METHODS OF USE THEREOF
|
EP1594530A4
(de)
|
2003-01-22 |
2006-10-11 |
Human Genome Sciences Inc |
Albuminfusionsproteine
|
AU2004208860A1
(en)
*
|
2003-02-06 |
2004-08-19 |
Novozymes A/S |
Human heavy chain antibody expression in filamentous fungi
|
US20050096264A1
(en)
*
|
2003-02-25 |
2005-05-05 |
Macdonald Lynn |
Methods for treating obesity and related conditions with glycoprotein hormone beta family hormones
|
JP4912144B2
(ja)
|
2003-03-12 |
2012-04-11 |
ジェネンテック, インコーポレイテッド |
造血促進のためのbv8及び/又はeg−vegfの使用
|
WO2004084816A2
(en)
*
|
2003-03-21 |
2004-10-07 |
Progenics Pharmaceuticals, Inc. |
IMPROVED CD4-IgG2 FORMULATIONS
|
WO2004085475A2
(en)
*
|
2003-03-24 |
2004-10-07 |
Zymogenetics, Inc. |
Anti-il-20 antibodies and binding partners and methods of using in inflammation
|
ES2327409T3
(es)
|
2003-03-26 |
2009-10-29 |
Apogenix Gmbh |
Proteinas de fusion fc mejoradas.
|
US20050037947A1
(en)
*
|
2003-05-06 |
2005-02-17 |
Bitonti Alan J. |
Inhibition of drug binding to serum albumin
|
US7348004B2
(en)
|
2003-05-06 |
2008-03-25 |
Syntonix Pharmaceuticals, Inc. |
Immunoglobulin chimeric monomer-dimer hybrids
|
TWI353991B
(en)
|
2003-05-06 |
2011-12-11 |
Syntonix Pharmaceuticals Inc |
Immunoglobulin chimeric monomer-dimer hybrids
|
HUE026384T2
(en)
*
|
2003-05-06 |
2016-06-28 |
Biogen Hemophilia Inc |
VII coagulation factor-FC chimeric proteins for the treatment of hemostasis disorder
|
EP1631266B1
(de)
|
2003-05-13 |
2011-03-16 |
DePuy Spine, Inc. |
Verfahren zur behandlung von degenerativer bandscheibenerkrankung
|
US7344716B2
(en)
|
2003-05-13 |
2008-03-18 |
Depuy Spine, Inc. |
Transdiscal administration of specific inhibitors of pro-inflammatory cytokines
|
US8273347B2
(en)
*
|
2003-05-13 |
2012-09-25 |
Depuy Spine, Inc. |
Autologous treatment of degenerated disc with cells
|
US7553827B2
(en)
*
|
2003-08-13 |
2009-06-30 |
Depuy Spine, Inc. |
Transdiscal administration of cycline compounds
|
US20040229878A1
(en)
*
|
2003-05-13 |
2004-11-18 |
Depuy Spine, Inc. |
Transdiscal administration of specific inhibitors of P38 kinase
|
JP5074030B2
(ja)
*
|
2003-05-13 |
2012-11-14 |
メルク セローノ ソシエテ アノニム |
Il−18結合タンパク質の活性変異体とその医学的応用
|
US7429378B2
(en)
*
|
2003-05-13 |
2008-09-30 |
Depuy Spine, Inc. |
Transdiscal administration of high affinity anti-MMP inhibitors
|
US7435808B2
(en)
|
2003-06-25 |
2008-10-14 |
Bristol-Myers Squibb Company |
Polynucleotides encoding novel adiponectin receptor variant, AdipoR2v2
|
PT1639011E
(pt)
*
|
2003-06-30 |
2009-01-20 |
Domantis Ltd |
Anticorpos (dab) de domínio único peguilados
|
WO2005007121A2
(en)
|
2003-07-18 |
2005-01-27 |
Massachusetts Institute Of Technology |
Mutant interleukin-2(il-2) polypeptides
|
US8361467B2
(en)
*
|
2003-07-30 |
2013-01-29 |
Depuy Spine, Inc. |
Trans-capsular administration of high specificity cytokine inhibitors into orthopedic joints
|
US8007805B2
(en)
*
|
2003-08-08 |
2011-08-30 |
Paladin Labs, Inc. |
Chimeric antigens for breaking host tolerance to foreign antigens
|
PL2520654T3
(pl)
|
2003-08-26 |
2017-08-31 |
The Regents Of The University Of Colorado, A Body Corporate |
Inhibitory aktywności proteazy serynowej i ich zastosowanie w sposobach i kompozycjach do leczenia zakażeń bakteryjnych
|
US20050069521A1
(en)
*
|
2003-08-28 |
2005-03-31 |
Emd Lexigen Research Center Corp. |
Enhancing the circulating half-life of interleukin-2 proteins
|
UA89481C2
(uk)
|
2003-09-30 |
2010-02-10 |
Центокор, Инк. |
Еритропоетинові міметичні шарнірно-серцевинні міметитіла людини, композиції, способи та застосування
|
US20070274988A1
(en)
*
|
2003-10-10 |
2007-11-29 |
Five Prime Therapeautics, Inc. |
Kiaa0779, Splice Variants Thereof, and Methods of Their Use
|
WO2005037999A2
(en)
*
|
2003-10-14 |
2005-04-28 |
Biogen Idec Ma Inc. |
Treatment of cancer using antibodies to lrrc15
|
US8129506B2
(en)
*
|
2003-10-24 |
2012-03-06 |
Genzyme Corporation |
Modulation of the interaction of MUC1 with MUC1 ligands
|
CA2545603A1
(en)
|
2003-11-12 |
2005-05-26 |
Biogen Idec Ma Inc. |
Neonatal fc receptor (fcrn)-binding polypeptide variants, dimeric fc binding proteins and methods related thereto
|
ATE555133T1
(de)
*
|
2003-11-13 |
2012-05-15 |
Hanmi Holdings Co Ltd |
Igg fc fragment für einen arzneimittelträger und verfahren zu dessen herstellung
|
US8110665B2
(en)
|
2003-11-13 |
2012-02-07 |
Hanmi Holdings Co., Ltd. |
Pharmaceutical composition comprising an immunoglobulin FC region as a carrier
|
US8895540B2
(en)
|
2003-11-26 |
2014-11-25 |
DePuy Synthes Products, LLC |
Local intraosseous administration of bone forming agents and anti-resorptive agents, and devices therefor
|
ES2305886T3
(es)
*
|
2003-12-30 |
2008-11-01 |
Merck Patent Gmbh |
Proteinas de fusion de il-7 con porciones de anticuerpo, su preparacion y su empleo.
|
EP1699821B1
(de)
*
|
2003-12-31 |
2012-06-20 |
Merck Patent GmbH |
Fc-ERYTHROPOIETIN-FUSIONSPROTEIN MIT VERBESSERTER PHARMAKOKINETIK
|
PT1706428E
(pt)
|
2004-01-22 |
2009-12-29 |
Merck Patent Gmbh |
Anticorpos anticancerígenos com fixação de complemento reduzida
|
MXPA06008918A
(es)
*
|
2004-02-06 |
2007-03-07 |
Astellas Llc |
Metodos de tratamiento de trastornos de la piel.
|
NZ549040A
(en)
*
|
2004-02-17 |
2009-07-31 |
Schering Corp |
Use for interleukin-33 (IL33) and the IL-33 receptor complex
|
US20100028995A1
(en)
*
|
2004-02-23 |
2010-02-04 |
Anaphore, Inc. |
Tetranectin Trimerizing Polypeptides
|
CA2563379A1
(en)
*
|
2004-03-31 |
2005-10-20 |
Centocor, Inc. |
Human glp-1 mimetibodies, compositions, methods and uses
|
US20080020383A1
(en)
*
|
2004-05-04 |
2008-01-24 |
Genaissance Pharmaceuticals, Inc. |
Haplotype Markers And Methods Of Using The Same To Determine Response To Treatment
|
US7662921B2
(en)
*
|
2004-05-07 |
2010-02-16 |
Astellas Us Llc |
Methods of treating viral disorders
|
US20060063208A1
(en)
|
2004-08-02 |
2006-03-23 |
Woolf Clifford J |
DRG11-responsive (DRAGON) gene and uses thereof
|
US7393662B2
(en)
|
2004-09-03 |
2008-07-01 |
Centocor, Inc. |
Human EPO mimetic hinge core mimetibodies, compositions, methods and uses
|
WO2006031689A2
(en)
*
|
2004-09-13 |
2006-03-23 |
Genzyme Corporation |
Multimeric constructs
|
BRPI0516011A
(pt)
*
|
2004-09-24 |
2008-08-19 |
Amgen Inc |
moléculas fc modificadas
|
WO2006047325A1
(en)
|
2004-10-21 |
2006-05-04 |
Genentech, Inc. |
Method for treating intraocular neovascular diseases
|
CN101198625A
(zh)
|
2004-10-22 |
2008-06-11 |
津莫吉尼蒂克斯公司 |
抗il-22ra抗体和结合伴侣及其在炎症中的使用方法
|
US20090311259A1
(en)
*
|
2004-11-17 |
2009-12-17 |
Victoria Smith |
Compositions and Methods for Treatment of Tumor of Hematopoietic Origin
|
BRPI0519000A2
(pt)
*
|
2004-12-09 |
2008-12-23 |
Merck Patent Gmbh |
variantes de il-7 com imunogenicidade reduzida
|
CN100515491C
(zh)
*
|
2005-01-04 |
2009-07-22 |
健能隆医药技术(上海)有限公司 |
白介素-22的医药用途
|
CN101137673B
(zh)
|
2005-01-05 |
2013-12-04 |
比奥根艾迪克Ma公司 |
Cripto结合分子
|
DE602006017071D1
(de)
|
2005-01-25 |
2010-11-04 |
Five Prime Therapeutics Inc |
Zusammensetzungen und verfahren zur behandlung von herzkrankheiten
|
WO2006084327A1
(en)
*
|
2005-02-09 |
2006-08-17 |
Apollo Life Sciences Limited |
A molecule and chimeric molecules thereof
|
KR100754667B1
(ko)
|
2005-04-08 |
2007-09-03 |
한미약품 주식회사 |
비펩타이드성 중합체로 개질된 면역글로불린 Fc 단편 및이를 포함하는 약제학적 조성물
|
US11254748B2
(en)
|
2005-04-15 |
2022-02-22 |
Macrogenics, Inc. |
Covalent diabodies and uses thereof
|
US9963510B2
(en)
|
2005-04-15 |
2018-05-08 |
Macrogenics, Inc. |
Covalent diabodies and uses thereof
|
EP1868650B1
(de)
*
|
2005-04-15 |
2018-10-03 |
MacroGenics, Inc. |
Kovalente diabodies und ihre verwendung
|
US9284375B2
(en)
|
2005-04-15 |
2016-03-15 |
Macrogenics, Inc. |
Covalent diabodies and uses thereof
|
PE20061324A1
(es)
|
2005-04-29 |
2007-01-15 |
Centocor Inc |
Anticuerpos anti-il-6, composiciones, metodos y usos
|
BRPI0611069A2
(pt)
|
2005-05-06 |
2010-11-09 |
Zymogenetics Inc |
anticorpo monoclonal, anticorpo humanizado, fragmento de anticorpo, uso de um antagonista, e, hibridoma
|
AU2006261185B2
(en)
|
2005-06-17 |
2012-02-16 |
Janssen Alzheimer Immunotherapy |
Methods of purifying anti A beta antibodies
|
EP2452694B1
(de)
|
2005-06-30 |
2018-11-14 |
Janssen Biotech, Inc. |
Anti-IL-23-Antikörper, Zusammensetzungen, Verfahren und Verwendung
|
MX2008000253A
(es)
|
2005-07-08 |
2008-04-02 |
Biogen Idec Inc |
Anticuerpos de sp35 y usos de los mismos.
|
CA2618951A1
(en)
*
|
2005-08-12 |
2007-02-22 |
Schering Corporation |
Mcp1 fusions
|
US8008453B2
(en)
|
2005-08-12 |
2011-08-30 |
Amgen Inc. |
Modified Fc molecules
|
WO2007025991A2
(en)
|
2005-09-01 |
2007-03-08 |
Ares Trading S.A. |
Treatment of optic neuritis
|
US20070104689A1
(en)
*
|
2005-09-27 |
2007-05-10 |
Merck Patent Gmbh |
Compositions and methods for treating tumors presenting survivin antigens
|
CA2623329A1
(en)
*
|
2005-10-13 |
2007-04-19 |
Virexx Medical Corp. |
Chimeric antigen containing hepatitis c virus polypeptide and fc fragment for eliciting an immune response
|
TW200722436A
(en)
*
|
2005-10-21 |
2007-06-16 |
Hoffmann La Roche |
A peptide-immunoglobulin-conjugate
|
JP2009515520A
(ja)
*
|
2005-11-10 |
2009-04-16 |
レセプター バイオロジックス, インコーポレイテッド |
肝細胞成長因子イントロン融合蛋白
|
ME00419B
(me)
|
2005-11-14 |
2011-10-10 |
Rinat Neuroscience Corp |
Antigonistička antitijela usmjerena protiv kalcitonita, peptida povezanog sa genom i postupkom njihovog korišćenja
|
EP1957536A2
(de)
*
|
2005-12-01 |
2008-08-20 |
Domantis Limited |
Nichtkompetitive domänenantikörperformate, die an den interleukin-1-rezeptor vom typ 1 binden
|
WO2007064911A1
(en)
*
|
2005-12-02 |
2007-06-07 |
Biogen Idec Inc. |
Anti-mouse cd20 antibodies and uses thereof
|
US20070161546A1
(en)
*
|
2005-12-15 |
2007-07-12 |
Colm King |
Methods and compositions for treatment of cancer
|
CA2634262A1
(en)
*
|
2005-12-22 |
2007-07-05 |
Dhy & Co., Ltd |
Antibodies against interleukin-22 binding protein and its uses
|
PT3219328T
(pt)
|
2005-12-29 |
2020-08-28 |
Janssen Biotech Inc |
Anticorpos anti-il-23 humana, composições, método e usos
|
KR101397290B1
(ko)
|
2005-12-30 |
2014-05-21 |
메르크 파텐트 게엠베하 |
감소한 면역원성을 가지는 항-cd19 항체
|
PL1966238T3
(pl)
*
|
2005-12-30 |
2012-09-28 |
Merck Patent Gmbh |
Warianty interleukiny-12p40 o polepszonej stabilności
|
US7514077B2
(en)
|
2006-01-10 |
2009-04-07 |
Zymogenetics, Inc. |
Methods of antagonizing signal transduction in dorsal root ganglion cells with IL-31 antagonists
|
US7625564B2
(en)
*
|
2006-01-27 |
2009-12-01 |
Novagen Holding Corporation |
Recombinant human EPO-Fc fusion proteins with prolonged half-life and enhanced erythropoietic activity in vivo
|
TW200738752A
(en)
|
2006-01-31 |
2007-10-16 |
Bayer Schering Pharma Ag |
Modulation of MDL-1 activity for treatment of inflammatory disease
|
GB0604187D0
(en)
*
|
2006-03-02 |
2006-04-12 |
Fusion Antibodies Ltd |
Peptide and uses thereof
|
EP2007538A4
(de)
*
|
2006-03-31 |
2011-04-20 |
Centocor Ortho Biotech Inc |
Bindungspartner mit modifzierten immunglobulindomänen für verlängerte halbwertzeit
|
WO2007135172A2
(en)
|
2006-05-24 |
2007-11-29 |
Laboratoires Serono S.A. |
Cladribine regimen for treating multiple sclerosis
|
BRPI0713272A2
(pt)
*
|
2006-06-12 |
2017-05-02 |
Receptor Biologix Inc |
produtos terapêuticos específicos ao receptor na superfície de pan-células
|
CA2656918A1
(en)
*
|
2006-06-22 |
2007-12-27 |
Vaccinex, Inc. |
Anti-c35 antibodies for treating cancer
|
WO2008036449A2
(en)
*
|
2006-06-29 |
2008-03-27 |
The Regents Of The University Of California |
Chemical antibodies for immunotherapy and imaging
|
EP2851064A3
(de)
|
2006-07-11 |
2015-08-05 |
Roy C. Levitt |
Prävention und Therapie von Rhinosinusitis mit proinflammatorischen Zytokinhemmern
|
US20080014285A1
(en)
*
|
2006-07-13 |
2008-01-17 |
Di Mauro Thomas M |
Method of treating neurodegenerative brain disease with a composite comprising superparamagnetic nanoparticles and a therapeutic compound
|
WO2008021237A1
(en)
|
2006-08-10 |
2008-02-21 |
Arubor Corporation |
Localized therapy of lower airways inflammatory disorders with proinflammatory cytokine inhibitors
|
JP2010500876A
(ja)
|
2006-08-18 |
2010-01-14 |
アブリンクス エン.ヴェー. |
Il−6媒介性シグナル伝達に関連する疾患及び障害の治療のための、il−6rに指向性を有するアミノ酸配列及びこれを含むポリペプチド
|
US7833527B2
(en)
*
|
2006-10-02 |
2010-11-16 |
Amgen Inc. |
Methods of treating psoriasis using IL-17 Receptor A antibodies
|
US20120282245A1
(en)
|
2006-10-03 |
2012-11-08 |
Biogen Idec Ma Inc. |
Biomarkers and assays for the treatment of cancer
|
AU2007353396C1
(en)
|
2006-11-02 |
2013-06-27 |
Biomolecular Holdings Llc |
Hybrid immunoglobulins with moving parts
|
CL2007003411A1
(es)
|
2006-11-28 |
2008-07-04 |
Centelion |
Proteina fusion que consiste en una region fc de una inmunoglobulina con un fragmento o dominio soluble de un receptor para fgf; polinucleotido que la codifica y vector y celula que lo comprenden; composicion farmaceutica que comprende la proteina fu
|
PL2436696T3
(pl)
|
2007-01-05 |
2017-10-31 |
Univ Zuerich |
Sposób wytwarzania specyficznych dla choroby cząsteczek wiążących i struktur docelowych
|
EP2740744B1
(de)
|
2007-01-09 |
2018-03-28 |
Biogen MA Inc. |
Sp35-Antikörper und Verwendungen dafür
|
EP2124988B1
(de)
|
2007-02-23 |
2014-11-12 |
The Trustees of Columbia University in the City of New York |
Verfahren zur aktivierung oder blockierung des hla-e/qa-1-eingeschränkten cd8+ t-zellregulatorweges zur behandlung von immunerkrankungen
|
EP2134834B1
(de)
*
|
2007-03-07 |
2013-04-17 |
GlycoFi, Inc. |
Herstellung von glycoproteinen mit modifizierter fucosylierung
|
US8492118B2
(en)
|
2007-05-11 |
2013-07-23 |
Altor Bioscience Corporation |
Fusion molecules and IL-15 variants
|
US7906149B2
(en)
*
|
2007-05-25 |
2011-03-15 |
Boval Company, L.P. |
Method for treating allergic dermatitis
|
WO2008149354A2
(en)
*
|
2007-06-04 |
2008-12-11 |
Rappaport Family Institute For Research In The Medical Sciences |
Agents for the treatment of inflammatory diseases and methods of using same
|
SG182170A1
(en)
*
|
2007-06-06 |
2012-07-30 |
Domantis Ltd |
Polypeptides, antibody variable domains and antagonists
|
US8067548B2
(en)
*
|
2007-07-26 |
2011-11-29 |
Novagen Holding Corporation |
Fusion proteins having mutated immunoglobulin hinge region
|
GB0717337D0
(en)
*
|
2007-09-06 |
2007-10-17 |
Ucb Pharma Sa |
Method of treatment
|
CN101970478A
(zh)
|
2007-10-11 |
2011-02-09 |
大学健康网络 |
调节SIRPα-CD47相互作用以增加造血干细胞植入以及用于此的化合物
|
WO2009052184A2
(en)
*
|
2007-10-16 |
2009-04-23 |
Receptor Biologix, Inc. |
Compositions comprising optimized her1 and her3 multimers and methods of use thereof
|
JP5298134B2
(ja)
|
2007-11-01 |
2013-09-25 |
パーシード セラピューティクス リミテッド ライアビリティ カンパニー |
免疫抑制ポリペプチドおよび核酸
|
WO2009061853A2
(en)
*
|
2007-11-05 |
2009-05-14 |
Massachusetts Institute Of Technology |
Mutant interleukin-2 (il-2) polypeptides
|
WO2009061807A2
(en)
|
2007-11-09 |
2009-05-14 |
Genentech, Inc. |
Activin receptor-like kinase-1 compositions and methods of use
|
HUE046564T2
(hu)
|
2007-11-21 |
2020-03-30 |
Univ Oregon Health & Science |
XI-es faktor elleni monoklonális antitestek és eljárások az alkalmazásukra
|
US20090312249A1
(en)
*
|
2007-12-06 |
2009-12-17 |
Korea Advanced Institute Of Science And Technology |
TLR4 decoy receptor protein
|
ES2570853T3
(es)
|
2007-12-07 |
2016-05-20 |
Zymogenetics Inc |
Moléculas de anticuerpo humanizadas específicas para IL-31
|
US8986696B2
(en)
*
|
2007-12-21 |
2015-03-24 |
Depuy Mitek, Inc. |
Trans-capsular administration of p38 map kinase inhibitors into orthopedic joints
|
US20090162351A1
(en)
*
|
2007-12-21 |
2009-06-25 |
Depuy Spine, Inc. |
Transdiscal administration of inhibitors of p38 MAP kinase
|
AU2009220900B2
(en)
|
2008-03-04 |
2014-09-11 |
Teva Pharmaceuticals International Gmbh |
Methods of treating chronic pain
|
US8669349B2
(en)
|
2008-04-02 |
2014-03-11 |
Macrogenics, Inc. |
BCR-complex-specific antibodies and methods of using same
|
ES2620285T3
(es)
*
|
2008-05-02 |
2017-06-28 |
Novartis Ag |
Moléculas de unión con base en fibronectina mejorada y usos de las mismas
|
CL2009001083A1
(es)
|
2008-05-06 |
2011-01-07 |
Genentech Inc |
Variantes de receptores de la proteina c3 de complemento (crig), molecula quimerica y composicion farmaceutica que las comprende; uso de las variantes para preparar un medicamento para prevenir o tratar una enfermedad asociada al complemento, tal como una enfermedad inflamatoria o autoinmune.
|
CA2726845C
(en)
*
|
2008-06-04 |
2017-09-26 |
Macrogenics, Inc. |
Antibodies with altered binding to fcrn and methods of using same
|
DK2982695T3
(da)
|
2008-07-09 |
2019-05-13 |
Biogen Ma Inc |
Sammensætninger, der omfatter antistoffer mod lingo eller fragmenter deraf
|
NZ590358A
(en)
|
2008-07-23 |
2012-04-27 |
Hanmi Holdings Co Ltd |
A polypeptide complex comprising non-peptidyl polymer having three functional ends
|
PL2949666T3
(pl)
|
2008-12-19 |
2019-07-31 |
Biogen International Neuroscience Gmbh |
Ludzkie przeciwciała przeciwko alfa-synukleinie
|
US20100159485A1
(en)
*
|
2008-12-19 |
2010-06-24 |
Centre For Dna Fingerprinting And Diagnostics |
Detection of mycobacterium tuberculosis
|
WO2010078526A1
(en)
|
2008-12-31 |
2010-07-08 |
Biogen Idec Ma Inc. |
Anti-lymphotoxin antibodies
|
JP2012521216A
(ja)
|
2009-03-24 |
2012-09-13 |
テバ バイオファーマスーティカルズ ユーエスエー,インコーポレーテッド |
Lightに対するヒト化抗体およびその使用
|
SG174891A1
(en)
|
2009-04-01 |
2011-11-28 |
Genentech Inc |
Treatment of insulin-resistant disorders
|
WO2010115995A2
(en)
|
2009-04-10 |
2010-10-14 |
Ablynx Nv |
Improved amino acid sequences directed against il-6r and polypeptides comprising the same for the treatment of il-6r related diseases and disorders
|
US8748581B2
(en)
|
2009-04-10 |
2014-06-10 |
Ablynx N.V. |
Anti-IL-6R polypeptides and pharmaceutical compositions thereof
|
KR20120030383A
(ko)
|
2009-04-22 |
2012-03-28 |
메르크 파텐트 게엠베하 |
변형된 FcRn 결합 자리를 갖는 항체 융합 단백질
|
BRPI1006443B1
(pt)
|
2009-04-22 |
2021-05-25 |
Alteogen, Inc |
Proteína ou peptídeo de fusão e método para aumentar a meia-vida in vivo de uma proteína ou peptídeo
|
WO2010129917A2
(en)
|
2009-05-08 |
2010-11-11 |
Vaccinex, Inc. |
Anti-cd100 antibodies and methods for using the same
|
PT2429574E
(pt)
|
2009-05-15 |
2015-07-17 |
Univ Health Network |
Composições e métodos para o tratamento de cancros hematológicos tendo como alvo a interacção sirp-cd47
|
HUE025294T2
(en)
*
|
2009-06-15 |
2016-02-29 |
Biokine Therapeutics Ltd |
New chemokine-binding polypeptides that are able to inhibit the process of autoimmunity, inflammation and cancer
|
WO2011019620A1
(en)
|
2009-08-10 |
2011-02-17 |
Genentech, Inc. |
Antibodies with enhanced adcc function
|
WO2011019622A1
(en)
|
2009-08-14 |
2011-02-17 |
Genentech, Inc. |
Cell culture methods to make antibodies with enhanced adcc function
|
IN2012DN02521A
(de)
|
2009-08-28 |
2015-08-28 |
Rinat Neuroscience Corp |
|
JP5898082B2
(ja)
|
2009-10-07 |
2016-04-06 |
マクロジェニクス,インコーポレーテッド |
フコシル化程度の変更により改良されたエフェクター機能を示すFc領域含有ポリペプチドおよびその使用法
|
TW201117824A
(en)
|
2009-10-12 |
2011-06-01 |
Amgen Inc |
Use of IL-17 receptor a antigen binding proteins
|
WO2011056502A1
(en)
|
2009-10-26 |
2011-05-12 |
Genentech, Inc. |
Bone morphogenetic protein receptor type ii compositions and methods of use
|
WO2011056497A1
(en)
|
2009-10-26 |
2011-05-12 |
Genentech, Inc. |
Activin receptor type iib compositions and methods of use
|
WO2011056494A1
(en)
|
2009-10-26 |
2011-05-12 |
Genentech, Inc. |
Activin receptor-like kinase-1 antagonist and vegfr3 antagonist combinations
|
US20110165122A1
(en)
*
|
2009-11-10 |
2011-07-07 |
The Regents Of The University Of California |
Method for targeted and sustained antiviral therapy
|
WO2011071957A1
(en)
|
2009-12-07 |
2011-06-16 |
Sea Lane Biotechnologies, Llc |
Conjugates comprising an antibody surrogate scaffold with improved pharmacokinetic properties
|
EP2516467A2
(de)
|
2009-12-23 |
2012-10-31 |
Emergent Product Development Seattle, LLC |
Zusammensetzungen mit tnf-alpha- und il-6-antagonisten und verwendungsverfahren dafür
|
US8637637B2
(en)
|
2010-01-12 |
2014-01-28 |
Bill Nai-Chau Sun |
Fc fusion proteins of human growth hormone
|
ES2652637T3
(es)
|
2010-01-15 |
2018-02-05 |
Kirin-Amgen, Inc. |
Formulación de anticuerpos y regímenes terapéuticos
|
WO2011103164A1
(en)
|
2010-02-18 |
2011-08-25 |
Centocor Ortho Biotech Inc. |
Monkey homolog of human interferon omega
|
US8802091B2
(en)
|
2010-03-04 |
2014-08-12 |
Macrogenics, Inc. |
Antibodies reactive with B7-H3 and uses thereof
|
ES2895480T3
(es)
|
2010-03-04 |
2022-02-21 |
Macrogenics Inc |
Anticuerpos reactivos con B7-H3, fragmentos inmunológicamente activos de los mismos y usos de los mismos
|
WO2011109280A1
(en)
|
2010-03-05 |
2011-09-09 |
Lerner Research Institute |
Methods and compositions to treat immune-mediated disorders
|
US10745467B2
(en)
|
2010-03-26 |
2020-08-18 |
The Trustees Of Dartmouth College |
VISTA-Ig for treatment of autoimmune, allergic and inflammatory disorders
|
US20150231215A1
(en)
|
2012-06-22 |
2015-08-20 |
Randolph J. Noelle |
VISTA Antagonist and Methods of Use
|
BR112012024565B1
(pt)
|
2010-03-26 |
2022-02-08 |
Trustees Of Dartmouth College |
Proteína de fusão vista imunossupressora multimérica isolada ou recombinante e composição
|
US20110250215A1
(en)
*
|
2010-04-02 |
2011-10-13 |
Athena Discovery, Inc. |
Structurally-related relaxin-fusion proteins with extended in vivo half-lives
|
JP5908888B2
(ja)
|
2010-04-16 |
2016-04-26 |
ヤンセン バイオテツク,インコーポレーテツド |
改変された植物のシステインプロテアーゼ及びその使用
|
US8524217B2
(en)
|
2010-05-11 |
2013-09-03 |
Merck Sharp & Dohme Corp. |
MCP1-Ig fusion variants
|
EP2582387A2
(de)
|
2010-06-17 |
2013-04-24 |
The United States Of America As Represented By The Secretary, National Institutes Of Health |
Zusammensetzungen und verfahren zur behandlung von entzündungserkrankungen
|
EP2591101B1
(de)
|
2010-07-09 |
2018-11-07 |
Bioverativ Therapeutics Inc. |
Systeme für faktor viii-verarbeitung und verfahren davon
|
JP5964300B2
(ja)
|
2010-08-02 |
2016-08-03 |
マクロジェニクス,インコーポレーテッド |
共有結合型ダイアボディおよびその使用
|
DK2601214T3
(en)
|
2010-08-06 |
2018-02-05 |
Genzyme Corp |
VEGF ANTAGONIST COMPOSITIONS AND APPLICATIONS THEREOF
|
KR101862236B1
(ko)
|
2010-09-02 |
2018-05-29 |
백시넥스 인코포레이티드 |
항-cxcl13 항체 및 이의 이용 방법
|
PT2918607T
(pt)
|
2010-09-21 |
2018-01-11 |
Altor Bioscience Corp |
Moléculas de fusão de il-15 multiméricas solúveis e métodos de produção e utilização das mesmas
|
US11053299B2
(en)
|
2010-09-21 |
2021-07-06 |
Immunity Bio, Inc. |
Superkine
|
JP6126991B2
(ja)
|
2010-09-27 |
2017-05-10 |
ヤンセン バイオテツク,インコーポレーテツド |
ヒトii型コラーゲンに結合する抗体
|
US8940272B2
(en)
|
2010-10-11 |
2015-01-27 |
University Of Zurich |
Human anti-tau antibodies
|
US8883134B2
(en)
*
|
2010-10-20 |
2014-11-11 |
Handok Pharmaceuticals, Inc. |
Human interleukin-1 receptor antagonist—hybrid Fc fusion protein
|
EP3214442A1
(de)
|
2010-10-25 |
2017-09-06 |
F. Hoffmann-La Roche AG |
Behandlung von gastrointestinalen entzündungen und psoriasis und asthmaentzündung und psoriasis a
|
JP5933573B2
(ja)
*
|
2010-11-08 |
2016-06-15 |
ノバルティス アーゲー |
Cxcr2結合ポリペプチド
|
EP3628689A1
(de)
|
2010-12-17 |
2020-04-01 |
Neurimmune Holding AG |
Humane anti-sod1 antikörper
|
NZ732970A
(en)
|
2011-05-20 |
2022-08-26 |
H Lundbeck As |
Use of anti-cgrp antibodies and antibody fragments to prevent or inhibit photophobia or light aversion in subjects in need thereof, especially migraine sufferers
|
CA2836799C
(en)
|
2011-05-20 |
2021-05-18 |
Alderbio Holdings Llc |
Use of anti-cgrp or anti-cgrp-r antibodies or antibody fragments to treat or prevent chronic and acute forms of diarrhea
|
PT2710039T
(pt)
|
2011-05-20 |
2019-04-23 |
Alderbio Holdings Llc |
Composições anti-cgrp e a sua utilização
|
EA201391753A1
(ru)
|
2011-05-21 |
2014-08-29 |
Макродженикс, Инк. |
Домены, связывающиеся с деиммунизованной сывороткой, и их применение для увеличения времени полужизни в сыворотке
|
JP6342325B2
(ja)
|
2011-05-25 |
2018-06-13 |
イナート・ファルマ・ソシエテ・アノニムInnate Pharma Pharma S.A. |
炎症性障害の治療のための抗kir抗体
|
SI2723379T1
(sl)
|
2011-06-23 |
2019-03-29 |
Biogen International Neuroscience Gmbh |
Molekule, ki se vežejo ma anti alfa-sinuklein
|
EP3628327A1
(de)
|
2011-06-24 |
2020-04-01 |
The Regents of the University of Colorado, A Body Corporate |
Zusammensetzungen, verfahren und verwendung für alpha-1-antitrypsin-fusionsmoleküle
|
MX2014000316A
(es)
*
|
2011-07-08 |
2014-02-19 |
Bayer Ip Gmbh |
Proteinas de fusion liberadoras de relaxina y usos de las mismas.
|
US9738707B2
(en)
|
2011-07-15 |
2017-08-22 |
Biogen Ma Inc. |
Heterodimeric Fc regions, binding molecules comprising same, and methods relating thereto
|
US20140234330A1
(en)
|
2011-07-22 |
2014-08-21 |
Amgen Inc. |
Il-17 receptor a is required for il-17c biology
|
DK2747782T3
(en)
*
|
2011-09-23 |
2018-04-23 |
Ablynx Nv |
Long-term inhibition of interleukin-6-mediated signal transmission
|
WO2013053775A1
(en)
|
2011-10-11 |
2013-04-18 |
Universität Zürich Prorektorat Mnw |
Combination medicament comprising il-12 and an agent for blockade of t-cell inhibitory molecules for tumour therapy
|
WO2013063155A2
(en)
|
2011-10-24 |
2013-05-02 |
Halozyme, Inc. |
Companion diagnostic for anti-hyaluronan agent therapy and methods of use thereof
|
WO2013106589A1
(en)
|
2012-01-10 |
2013-07-18 |
The Regents Of The University Of Colorado, A Body Corporate |
Compositions, methods and uses for alpha-1 antitrypsin fusion molecules
|
US9890213B2
(en)
|
2012-03-02 |
2018-02-13 |
Vaccinex, Inc. |
Methods for the treatment of B cell-mediated inflammatory diseases
|
US9289507B2
(en)
|
2012-05-17 |
2016-03-22 |
Extend Biosciences, Inc. |
Carriers for improved drug delivery
|
DK2852610T3
(en)
|
2012-05-23 |
2018-09-03 |
Glykos Finland Oy |
PRODUCTION OF FUCOSYLED GLYCOPROTEIN
|
US9890215B2
(en)
|
2012-06-22 |
2018-02-13 |
King's College London |
Vista modulators for diagnosis and treatment of cancer
|
EP2864352B1
(de)
|
2012-06-22 |
2018-08-08 |
The Trustees Of Dartmouth College |
Neuartige vista-ig-konstrukte und verwendung von vista-ig zur behandlung von autoimmun-, allergischen und entzündungserkrankungen
|
WO2014011775A1
(en)
|
2012-07-10 |
2014-01-16 |
The Trustees Of The University Of Pennsylvania |
Biomaterials for enhanced implant-host integration
|
ES2771324T3
(es)
|
2012-08-03 |
2020-07-06 |
Dana Farber Cancer Inst Inc |
Usos médicos de agentes que modulan la activación de las células inmunitarias y métodos de detección correspondientes
|
KR102312856B1
(ko)
|
2012-08-24 |
2021-10-13 |
더 리젠츠 오브 더 유니버시티 오브 캘리포니아 |
Ror1 암을 치료하고 전이를 저해하는데 이용을 위한 항체와 백신
|
CN109793893B
(zh)
|
2012-09-07 |
2023-05-26 |
达特茅斯大学理事会 |
用于诊断和治疗癌症的vista调节剂
|
US9278124B2
(en)
|
2012-10-16 |
2016-03-08 |
Halozyme, Inc. |
Hypoxia and hyaluronan and markers thereof for diagnosis and monitoring of diseases and conditions and related methods
|
PL3575326T3
(pl)
|
2012-12-17 |
2022-07-11 |
Pf Argentum Ip Holdings Llc |
Leczenie komórek chorobowych cd47+ z użyciem fuzji sirp alfa-fc
|
EP3792278A3
(de)
|
2012-12-21 |
2021-05-26 |
Biogen MA Inc. |
Menschliche anti-tau-antikörper
|
WO2014102399A1
(en)
|
2012-12-31 |
2014-07-03 |
Neurimmune Holding Ag |
Recombinant human antibodies for therapy and prevention of polyomavirus-related diseases
|
US9487587B2
(en)
|
2013-03-05 |
2016-11-08 |
Macrogenics, Inc. |
Bispecific molecules that are immunoreactive with immune effector cells of a companion animal that express an activating receptor and cells that express B7-H3 and uses thereof
|
WO2014137355A1
(en)
|
2013-03-08 |
2014-09-12 |
Vaccinex, Inc. |
Anti-cxcl13 antibodies and associated epitope sequences
|
JOP20140087B1
(ar)
|
2013-03-13 |
2021-08-17 |
Amgen Inc |
بروتينات مخصصة ل baff و b7rp1 وإستخداماتها
|
US9458246B2
(en)
|
2013-03-13 |
2016-10-04 |
Amgen Inc. |
Proteins specific for BAFF and B7RP1
|
JP6676521B2
(ja)
|
2013-03-14 |
2020-04-08 |
マクロジェニクス,インコーポレーテッド |
二重特異性分子、薬学的組成物及びそれらの使用
|
CA2899089C
(en)
|
2013-03-15 |
2021-10-26 |
Biogen Ma Inc. |
Factor ix polypeptide formulations
|
DK3460054T3
(da)
|
2013-03-15 |
2021-01-18 |
Atyr Pharma Inc |
Histidyl-tRNA-syntetase-Fc-konjugater
|
PT2970422T
(pt)
|
2013-03-15 |
2018-07-06 |
Hoffmann La Roche |
Polipéptidos il-22 e proteínas de fusão il-22 fc e métodos de utilização
|
HUE052232T2
(hu)
|
2013-05-06 |
2021-04-28 |
Scholar Rock Inc |
Készítmények és eljárások növekedési faktor modulálására
|
CA2913490A1
(en)
|
2013-06-06 |
2014-12-11 |
Dana-Farber Cancer Institute, Inc. |
Compositions and methods for identification, assessment, prevention, and treatment of cancer using pd-l1 isoforms
|
AR096891A1
(es)
|
2013-07-12 |
2016-02-03 |
Hanmi Pharm Ind Co Ltd |
Conjugado de monómero polipéptido biológicamente activo y conjugado de fragmento fc de inmunoglobulina, que muestra aclaramiento mediado por receptor reducido, y el método para la preparación del mismo
|
UA116479C2
(uk)
|
2013-08-09 |
2018-03-26 |
Макродженікс, Інк. |
БІСПЕЦИФІЧНЕ МОНОВАЛЕНТНЕ Fc-ДІАТІЛО, ЯКЕ ОДНОЧАСНО ЗВ'ЯЗУЄ CD32B I CD79b, ТА ЙОГО ЗАСТОСУВАННЯ
|
US11384149B2
(en)
|
2013-08-09 |
2022-07-12 |
Macrogenics, Inc. |
Bi-specific monovalent Fc diabodies that are capable of binding CD32B and CD79b and uses thereof
|
EP2839842A1
(de)
|
2013-08-23 |
2015-02-25 |
MacroGenics, Inc. |
Bispezifische monovalente Diabodies mit Fähigkeit zur Bindung von CD123 und CD3 und Verwendungen davon
|
EP2840091A1
(de)
|
2013-08-23 |
2015-02-25 |
MacroGenics, Inc. |
Bispezifische Diabodies, die gpA33 und CD3 binden können und Anwendungen dieser
|
EP3757130A1
(de)
|
2013-09-26 |
2020-12-30 |
Costim Pharmaceuticals Inc. |
Verfahren zur behandlung von blutkrebs
|
US20160297875A1
(en)
|
2013-12-07 |
2016-10-13 |
Case Western Reserve University |
Compositions and methods of treating thrombosis
|
US11708411B2
(en)
|
2013-12-20 |
2023-07-25 |
Wake Forest University Health Sciences |
Methods and compositions for increasing protective antibody levels induced by pneumococcal polysaccharide vaccines
|
US11014987B2
(en)
|
2013-12-24 |
2021-05-25 |
Janssen Pharmaceutics Nv |
Anti-vista antibodies and fragments, uses thereof, and methods of identifying same
|
KR102534681B1
(ko)
|
2013-12-24 |
2023-05-18 |
잔센파마슈티카엔.브이. |
항-vista 항체 및 단편
|
US10047133B2
(en)
*
|
2014-01-22 |
2018-08-14 |
Antagonis Biotherapeutics Gmbh |
Glycosaminoglycan-antagonising fusion proteins and methods of using same
|
US10556945B2
(en)
|
2014-03-21 |
2020-02-11 |
Teva Pharmaceuticals International Gmbh |
Antagonist antibodies directed against calcitonin gene-related peptide and methods using same
|
FI3119431T3
(fi)
|
2014-03-21 |
2024-03-20 |
Teva Pharmaceuticals Int Gmbh |
Kalsitoniinigeeniin liittyvää peptidiä vastaan suunnattuja antagonisti-vasta-aineita ja menetelmiä niiden käyttämiseksi
|
JP6596014B2
(ja)
|
2014-03-31 |
2019-10-23 |
アムジェン ケー・エー,インコーポレイテッド |
爪および頭皮乾癬の治療方法
|
WO2015191881A2
(en)
|
2014-06-11 |
2015-12-17 |
Green Kathy A |
Use of vista agonists and antagonists to suppress or enhance humoral immunity
|
PL3160498T3
(pl)
|
2014-06-30 |
2022-02-21 |
Altor Bioscience Corporation |
Cząsteczki na bazie IL-15 i sposoby ich zastosowania
|
CN108064266A
(zh)
|
2014-07-21 |
2018-05-22 |
格利科斯芬兰公司 |
在丝状真菌中具有哺乳动物样n-聚糖的糖蛋白的制备
|
WO2016022597A1
(en)
|
2014-08-04 |
2016-02-11 |
Case Western Reserve University |
Targeting peptides and methods of use
|
US9616114B1
(en)
|
2014-09-18 |
2017-04-11 |
David Gordon Bermudes |
Modified bacteria having improved pharmacokinetics and tumor colonization enhancing antitumor activity
|
BR112017006515A8
(pt)
|
2014-09-29 |
2018-02-27 |
Univ Duke |
moléculas biespecíficas, composições, método para tratar ou prevenir infecção por hiv-1 em um indivíduo com essa necessidade, e vetor
|
WO2016050822A2
(en)
|
2014-09-30 |
2016-04-07 |
Neurimmune Holding Ag |
Human-derived anti-dipeptide repeats (dprs) antibody
|
WO2016062766A1
(en)
|
2014-10-21 |
2016-04-28 |
Ablynx Nv |
Treatment of il-6r related diseases
|
US9789197B2
(en)
|
2014-10-22 |
2017-10-17 |
Extend Biosciences, Inc. |
RNAi vitamin D conjugates
|
WO2016065052A1
(en)
|
2014-10-22 |
2016-04-28 |
Extend Biosciences, Inc. |
Insulin vitamin d conjugates
|
WO2016065042A1
(en)
|
2014-10-22 |
2016-04-28 |
Extend Biosciences, Inc. |
Therapeutic vitamin d conjugates
|
AU2015357463B2
(en)
|
2014-12-05 |
2021-10-07 |
Immunext, Inc. |
Identification of VSIG8 as the putative vista receptor and its use thereof to produce vista/VSIG8 modulators
|
CN107407677B
(zh)
|
2015-01-28 |
2020-07-17 |
豪夫迈·罗氏有限公司 |
多发性硬化的基因表达标志和治疗
|
US11820807B2
(en)
|
2015-06-12 |
2023-11-21 |
Ubi Pharma Inc |
Immunoglobulin fusion proteins and uses thereof
|
BR112017027870A2
(pt)
|
2015-06-24 |
2018-08-28 |
Janssen Pharmaceutica Nv |
anticorpos e fragmentos anti-vista
|
BR112018001353A2
(pt)
|
2015-08-07 |
2018-09-11 |
Alexo Therapeutics, Inc. |
construtos tendo um domínio de sirp-alfa ou variante do mesmo
|
IL258009B2
(en)
|
2015-09-15 |
2024-03-01 |
Univ Texas |
Antibodies that bind receptors on T cells (TCR) and their use
|
US11338065B2
(en)
|
2015-10-08 |
2022-05-24 |
Massachusetts Institute Of Technology |
In situ expansion of engineered devices for regeneration
|
US11207393B2
(en)
|
2015-10-16 |
2021-12-28 |
President And Fellows Of Harvard College |
Regulatory T cell PD-1 modulation for regulating T cell effector immune responses
|
US10646465B2
(en)
|
2015-12-17 |
2020-05-12 |
Biokine Therapeutics Ltd. |
Small molecules against cancer
|
MX2018007361A
(es)
|
2015-12-17 |
2019-05-16 |
Biokine Therapeutics Ltd |
Moléculas pequeñas para inhibir la actividad de quimiocinas, la actividad de una cinasa y/o el crecimiento de células cancerosas.
|
WO2017117558A1
(en)
|
2015-12-31 |
2017-07-06 |
The Regents Of The University Of Colorado, A Body Corporate |
Methods and uses for alpha-1 antitrypsin or recombinant forms thereof, on steroid-refractory graft versus host disease involving gastrointestinal complications
|
BR112018016461A2
(pt)
|
2016-02-12 |
2019-10-01 |
Janssen Pharmaceutica Nv |
anticorpos e fragmentos anti-vista, usos dos mesmos e métodos de identificação dos mesmos
|
US11072652B2
(en)
|
2016-03-10 |
2021-07-27 |
Viela Bio, Inc. |
ILT7 binding molecules and methods of using the same
|
CR20180537A
(es)
|
2016-04-15 |
2019-03-04 |
Immunext Inc |
Anticuerpos vista antihumanos y su uso
|
AU2017249435A1
(en)
|
2016-04-15 |
2018-10-25 |
Macrogenics, Inc. |
Novel B7-H3 binding molecules, antibody drug conjugates thereof and methods of use thereof
|
AU2017271593B2
(en)
|
2016-05-27 |
2021-04-22 |
Altor Bioscience Corporation |
Construction and characterization of multimeric IL-15-based molecules with CD3 binding domains
|
JP2018035137A
(ja)
|
2016-07-13 |
2018-03-08 |
マブイミューン ダイアグノスティックス エイジーMabimmune Diagnostics Ag |
新規な抗線維芽細胞活性化タンパク質(fap)結合薬剤およびその使用
|
PE20191148A1
(es)
|
2016-09-23 |
2019-09-02 |
Teva Pharmaceuticals Int Gmbh |
Tratamiento de la migrana refractaria
|
US20180200366A1
(en)
|
2016-10-21 |
2018-07-19 |
Altor Bioscience Corporation |
Multimeric il-15-based molecules
|
US11180535B1
(en)
|
2016-12-07 |
2021-11-23 |
David Gordon Bermudes |
Saccharide binding, tumor penetration, and cytotoxic antitumor chimeric peptides from therapeutic bacteria
|
US11129906B1
(en)
|
2016-12-07 |
2021-09-28 |
David Gordon Bermudes |
Chimeric protein toxins for expression by therapeutic bacteria
|
CN110234351A
(zh)
|
2017-01-30 |
2019-09-13 |
詹森生物科技公司 |
用于治疗活动性银屑病关节炎的抗tnf抗体、组合物和方法
|
US11649288B2
(en)
|
2017-02-07 |
2023-05-16 |
Seattle Children's Hospital |
Phospholipid ether (PLE) CAR T cell tumor targeting (CTCT) agents
|
MX2019009377A
(es)
|
2017-02-07 |
2019-12-11 |
Janssen Biotech Inc |
Anticuerpos anti-tnf, composiciones y metodos para el tratamiento de la espondilitis anquilosante activa.
|
US11850262B2
(en)
|
2017-02-28 |
2023-12-26 |
Purdue Research Foundation |
Compositions and methods for CAR T cell therapy
|
CA3054733A1
(en)
|
2017-02-28 |
2018-09-07 |
Sanofi |
Therapeutic rna
|
WO2018165208A1
(en)
|
2017-03-06 |
2018-09-13 |
Altor Bioscience Corporation |
Il-15-based fusions to il-12 and il-18
|
US20190048055A1
(en)
|
2017-03-31 |
2019-02-14 |
Altor Bioscience Corporation |
Alt-803 in combination with anti-cd38 antibody for cancer therapies
|
CN110536694A
(zh)
|
2017-04-20 |
2019-12-03 |
Atyr 医药公司 |
用于治疗肺部炎症的组合物和方法
|
JP7246320B2
(ja)
|
2017-05-05 |
2023-03-27 |
バクシネックス インコーポレーティッド |
ヒト抗セマフォリン4d抗体
|
EP3676289A4
(de)
|
2017-08-28 |
2021-05-05 |
Altor Bioscience LLC |
Il-15-basierte fusionen zu il-7 und il-21
|
JP7417542B2
(ja)
|
2018-01-22 |
2024-01-18 |
シアトル チルドレンズ ホスピタル (ディービーエイ シアトル チルドレンズ リサーチ インスティテュート) |
Car t細胞の使用方法
|
HUE060435T2
(hu)
|
2018-01-26 |
2023-03-28 |
Hoffmann La Roche |
IL-22 Fc készítmények és alkalmazásukra szolgáló eljárások
|
AU2019212709A1
(en)
|
2018-01-26 |
2020-08-13 |
Genentech, Inc. |
IL-22 Fc fusion proteins and methods of use
|
CA3091139A1
(en)
|
2018-02-21 |
2019-08-29 |
Genentech, Inc. |
Dosing for treatment with il-22 fc fusion proteins
|
CA3089333C
(en)
|
2018-03-26 |
2023-10-10 |
Altor Bioscience Llc |
Anti-pdl1, il-15 and tgf-beta receptor combination molecules
|
EP3792276A4
(de)
|
2018-04-26 |
2022-02-16 |
Good T Cells, Inc. |
Neuartiges fusionsprotein und pharmazeutische zusammensetzung zur vorbeugung oder behandlung von krebs damit
|
EP3815706A4
(de)
*
|
2018-06-28 |
2022-03-16 |
National University Corporation Okayama University |
Mittel zur verbesserung der phagozytosefähigkeit von neutrophilen
|
CA3107159A1
(en)
|
2018-07-24 |
2020-01-30 |
Good T Cells, Inc. |
Composition for preventing or treating immune-related diseases
|
CN110964116A
(zh)
|
2018-09-26 |
2020-04-07 |
北京辅仁瑞辉生物医药研究院有限公司 |
GLP1-Fc融合蛋白及其缀合物
|
CR20210373A
(es)
|
2019-01-08 |
2021-08-19 |
H Lundbeck As |
Tratamiento agudo y tratamiento rápido de la cefalea usando anticuerpos anti-cgrp
|
AU2020208828A1
(en)
|
2019-01-15 |
2021-08-05 |
Janssen Biotech, Inc. |
Anti-TNF antibody compositions and methods for the treatment of juvenile idiopathic arthritis
|
CA3127748A1
(en)
|
2019-01-23 |
2020-07-30 |
Janssen Biotech, Inc. |
Anti-tnf antibody compositions for use in methods for the treatment of psoriatic arthritis
|
WO2020167912A1
(en)
|
2019-02-13 |
2020-08-20 |
The Brigham And Women's Hospital, Inc. |
Anti-peripheral lymph node addressin antibodies and uses thereof
|
CA3133388A1
(en)
|
2019-03-14 |
2020-09-17 |
Janssen Biotech, Inc. |
Methods for producing anti-tnf antibody compositions
|
WO2020183269A1
(en)
|
2019-03-14 |
2020-09-17 |
Janssen Biotech, Inc. |
Manufacturing methods for producing anti-tnf antibody compositions
|
US20220144934A1
(en)
|
2019-03-14 |
2022-05-12 |
Janssen Biotech, Inc. |
Methods for Producing Anti-TNF Antibody Compositions
|
CA3090315C
(en)
|
2019-05-15 |
2023-09-19 |
Biokine Therapeutics Ltd. |
8-phenoxy-quinolinone derivatives for treating cancer, inhibiting chemokine activity and/or inducing cell death
|
CA3138241A1
(en)
|
2019-05-23 |
2020-11-26 |
Janssen Biotech, Inc. |
Method of treating inflammatory bowel disease with a combination therapy of antibodies to il-23 and tnf alpha
|
KR20220044904A
(ko)
|
2019-05-31 |
2022-04-12 |
알렉소 온콜로지 인크. |
면역 관문 억제제와 병용하는 sirp 알파 fc 융합으로 암을 치료하는 방법
|
MX2021014885A
(es)
|
2019-06-03 |
2022-04-06 |
Janssen Biotech Inc |
Composiciones de anticuerpos anti-tnf, y métodos para el tratamiento de la artritis psoriásica.
|
JP2022535534A
(ja)
|
2019-06-03 |
2022-08-09 |
ヤンセン バイオテツク,インコーポレーテツド |
活動性強直性脊椎炎を治療するための抗tnf抗体、組成物、及び方法
|
WO2021028752A1
(en)
|
2019-08-15 |
2021-02-18 |
Janssen Biotech, Inc. |
Anti-tfn antibodies for treating type i diabetes
|
BR112022017718A2
(pt)
|
2020-03-05 |
2022-11-16 |
Diamedica Usa Inc |
Polipeptídeos de ulinastatina
|
WO2021207662A1
(en)
|
2020-04-10 |
2021-10-14 |
Genentech, Inc. |
Use of il-22fc for the treatment or prevention of pneumonia, acute respiratory distress syndrome, or cytokine release syndrome
|
WO2021230233A1
(ja)
*
|
2020-05-14 |
2021-11-18 |
学校法人日本医科大学 |
感染症の治療又は予防剤
|
WO2022261183A2
(en)
|
2021-06-08 |
2022-12-15 |
Dana-Farber Cancer Institute, Inc. |
Compositions and methods for treating and/or identifying an agent for treating intestinal cancers
|
AU2022308201A1
(en)
|
2021-07-09 |
2024-02-22 |
Janssen Biotech, Inc. |
Manufacturing methods for producing anti-tnf antibody compositions
|
AU2022306144A1
(en)
|
2021-07-09 |
2024-02-22 |
Janssen Biotech, Inc. |
Manufacturing methods for producing anti-tnf antibody compositions
|
WO2023097119A2
(en)
|
2021-11-29 |
2023-06-01 |
Dana-Farber Cancer Institute, Inc. |
Methods and compositions to modulate riok2
|
WO2023168426A1
(en)
|
2022-03-03 |
2023-09-07 |
Enosi Therapeutics Corporation |
Compositions and cells containing mixtures of oligo-trap fusion proteins (ofps) and uses thereof
|
WO2023173084A1
(en)
|
2022-03-11 |
2023-09-14 |
University Of Rochester |
Cyclopeptibodies and uses thereof
|
KR20230156844A
(ko)
|
2022-05-02 |
2023-11-14 |
노보 노르디스크 에이/에스 |
고농도 조성물 및 피하 투여에 적합한 신규한 항-angptl3 항체
|